[{"text": "CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study Zacks Equity Research Thu, Jan 23, 2025, 7:19 PM 4 Minuten Lesezeit In diesem Artikel: CYTK -2.01% Shares of Cytokinetics CYTK gained 2.2% on Wednesday after the company began enrolling patients in its mid-stage study of CK-4021586 (CK-586), a cardiac myosin inhibitor, for treating heart failure patients. The intended patient population includes those with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) \u226560%. The primary goal of the phase II AMBER-HFpEF study is to evaluate the safety and tolerability profile of CK-586 compared to placebo in HFpEF patients. As secondary objectives, the study will also assess the effect of CK-586 on LVEF and NT-proBNP, and determine the candidate\u2019s pharmacokinetics\u00a0and pharmacokinetic/pharmacodynamic relationship. Other exploratory endpoints of the study include evaluating the effect of CK-586 on patient function, symptoms and measures of cardiac function. Cytokinetics plans to enroll approximately 60 HFpEF patients in the phase II AMBER-HFpEF study who will receive CK-586 or placebo in three dose escalation cohorts. In the past three months, CYTK shares have lost 10.6% compared with the industry\u2019s 8.7% decline. Zacks Investment Research Image Source: Zacks Investment Research CYTK\u2019s Other Pipeline Developmental Programs Cytokinetics is developing its lead investigational candidate, aficamten, a novel, oral and small-molecule cardiac myosin inhibitor, to reduce the hypercontractility associated with\u00a0hypertrophic cardiomyopathy (HCM). A regulatory filing for aficamten to treat obstructive HCM is currently under review by the FDA. A final decision from the regulatory body is expected on Sept. 26, 2025. The FDA also informed the company that it is not planning to hold an advisory committee meeting to discuss the application. Similar regulatory filings seeking approval for aficamten to treat obstructive HCM are also currently under review in other geographies, including the EU. Cytokinetics is also evaluating aficamten monotherapy in its phase III MAPLE-HCM study compared to metoprolol monotherapy in patients with obstructive HCM (enrollment completed) and ACACIA-HCM, a phase III study of aficamten in patients with non-obstructive HCM (enrolment ongoing). Other studies include CEDAR-HCM, a clinical study of aficamten in a pediatric population with obstructive HCM. Enrollment is ongoing in CEDAR-HCM. Another pipeline candidate is omecamtiv mecarbil, a cardiac muscle activator, which is being developed for patients with heart failure. Last month, Cytokinetics initiated COMET-HF, a confirmatory phase III study to assess the efficacy and safety of the candidate in patients with symptomatic heart failure with severely reduced ejection fraction. Weiterlesen Cytokinetics, Incorporated Price and Consensus Cytokinetics, Incorporated Price and Consensus Cytokinetics, Incorporated price-consensus-chart | Cytokinetics, Incorporated Quote CYTK\u2019 Zacks Rank & Stocks to Consider Cytokinetics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, BioMarin Pharmaceutical BMRN and CytomX Therapeutics CTMX. While CSTL and BMRN currently sport a Zacks Rank #1 (Strong Buy) each, CTMX carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 30 days, Castle Biosciences\u2019 earnings estimates for 2024 have increased from 34 cents to 39 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 16.3%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 30 days, estimates for BioMarin Pharmaceutical\u2019s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 11.9%. BMRN\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%. In the past 30 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 22.4%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research Kommentare anzeigen AGB und Datenschutzerkl\u00e4rung Privacy Dashboard Empfohlene Nachrichtenartikel", "symbol": "CTMX", "date": "2025-01-23T16:19:00+00:00", "sentiment": {"score": 0.05635508894920349, "confidence": 0.3756867051124573, "probabilities": {"positive": 0.3756867051124573, "negative": 0.3193316161632538, "neutral": 0.30498164892196655}}, "embedding": [-0.059891752898693085, -0.041126590222120285, -0.012921972200274467, -0.07770005613565445, 0.03281869739294052, -0.05510471761226654, -0.1524418592453003, 0.2989131808280945, 0.08984033763408661, -0.0019909804686903954, -0.053308114409446716, -0.008371653966605663, 0.0846380889415741, 0.03124259226024151, -0.032819412648677826, -0.036313630640506744, 0.11167042702436447, 0.12682533264160156, -0.14894415438175201, 0.11539454758167267, -0.04830744117498398, -0.006132302340120077, 0.046805016696453094, 0.07615666836500168, -0.13608255982398987, 0.004761969204992056, -0.16936545073986053, 0.03547435253858566, -0.12696637213230133, 0.0333511047065258, 0.012937594205141068, 0.08335995674133301, 0.07149113714694977, 0.07659842073917389, 0.019404588267207146, 0.06674986332654953, -0.15566110610961914, -0.06762614846229553, -0.1856020987033844, -0.04594193771481514, 0.0371382050216198, -0.0732252299785614, -0.15191802382469177, 0.062240809202194214, 0.18940699100494385, -0.06768214702606201, -0.08154043555259705, -0.0016179056838154793, -0.08614565432071686, 0.19041474163532257, -0.12082232534885406, -0.04952019453048706, 0.05038077384233475, 0.15222331881523132, -0.0730883777141571, -0.016445573419332504, -0.26790234446525574, -0.013314230367541313, 0.08579336851835251, 0.006053708493709564, -0.10089738667011261, 0.0496230348944664, -0.06394867599010468, -0.03852252662181854, 0.07590638101100922, 0.030534090474247932, -0.03611254319548607, 0.0003410112112760544, 0.03420080989599228, -0.021936899051070213, 0.06906773149967194, -0.148867666721344, -0.06924117356538773, 0.12564381957054138, -0.018862657248973846, 0.13763174414634705, 0.08549375832080841, 0.04295491799712181, -0.033130183815956116, -0.24143728613853455, 0.08954820036888123, 0.028252078220248222, 0.018150245770812035, -0.0030659567564725876, -0.049111492931842804, 0.04004472866654396, 0.0017598671838641167, 0.18292444944381714, -0.020331187173724174, 0.0882565975189209, 0.1814582347869873, 0.1065424382686615, 0.06404639035463333, -0.023720599710941315, 0.05927556753158569, -0.05043492466211319, -0.03365981578826904, 0.07906545698642731, -0.004777434282004833, -0.022185245528817177, 0.08047305047512054, 0.0060335430316627026, -0.1592826545238495, -0.14769232273101807, 0.025912629440426826, -0.13966278731822968, 0.06028904765844345, -0.049501724541187286, 0.10694004595279694, -0.005933810956776142, -0.012633622623980045, -0.040188830345869064, -0.03889673948287964, -0.0907726138830185, 0.11938204616308212, 0.3117383122444153, -0.014778362587094307, -0.01626507192850113, 0.2922021746635437, 0.07013247907161713, 0.06918024271726608, -0.12316489219665527, 0.04626147076487541, -0.09916514903306961, -0.08376604318618774, 0.14198845624923706, -0.12957701086997986, 1.4090474459154137e-32, 0.0015868842601776123, 0.033265121281147, 0.10606653988361359, 0.016608411446213722, 0.027945270761847496, -0.13391339778900146, 0.11124290525913239, -0.0851660817861557, -0.030796140432357788, -0.13977545499801636, -0.1292448341846466, -0.004504688084125519, -0.036136504262685776, -0.03379601985216141, -0.26096323132514954, -0.10107366740703583, -0.11679048836231232, -0.00496597308665514, -0.07604263722896576, 0.0843786969780922, 0.08246325701475143, -0.05877949297428131, -0.061830244958400726, -0.027390312403440475, -0.032337985932826996, 0.08257857710123062, -0.05718722194433212, 0.15428219735622406, -0.05222674086689949, 0.06631705909967422, -0.10694784671068192, 0.02884913980960846, -0.0255950465798378, -0.15832284092903137, -0.10680212825536728, -0.15545380115509033, -0.060795366764068604, -0.033659983426332474, 0.022756021469831467, 0.027691103518009186, -0.09852804243564606, -0.014503631740808487, -0.08592945337295532, -0.07523484528064728, 0.2004719227552414, -0.1080508679151535, -0.003852319438010454, 0.017368396744132042, -0.07756539434194565, -0.0025145234540104866, 0.08377313613891602, -0.09708954393863678, 0.0005774535238742828, -0.0505642332136631, -0.06060300022363663, 0.06111311912536621, -0.10456252098083496, -0.06096015125513077, 0.03475160896778107, 0.05108049884438515, 0.02860512211918831, 0.057090599089860916, 0.027251102030277252, 0.09066051244735718, -0.08031132817268372, 0.08783702552318573, -0.15071816742420197, -0.09581727534532547, -0.2390231490135193, 0.10018003731966019, 0.00317292008548975, -0.052990369498729706, 0.15249451994895935, -0.04962491989135742, 0.21638214588165283, -0.04566745460033417, -0.011182907037436962, 0.24678128957748413, -0.057144295424222946, -0.02494439110159874, 0.005145726725459099, 0.004694515839219093, -0.1232633888721466, 0.04860188439488411, 0.020017197355628014, -0.1385221630334854, 0.08165785670280457, -0.013023876585066319, -0.20130014419555664, -0.07279346883296967, 0.11921493709087372, -0.1063106581568718, 0.02414940483868122, 0.14109720289707184, 0.021910857409238815, -1.4718790883348035e-32, -0.06168672814965248, 0.11859355866909027, 0.030705679208040237, -0.07406559586524963, 0.03285465016961098, 0.08236993104219437, 0.15671686828136444, -0.10921773314476013, 0.24291542172431946, -0.0429476760327816, 0.15389125049114227, 0.0013936539180576801, -0.050112105906009674, 0.015224865637719631, -0.15201500058174133, 0.08816574513912201, -0.12391988188028336, -0.030661052092909813, -0.098026804625988, 0.16797909140586853, 0.04747756943106651, -0.056190311908721924, -0.06978107243776321, 0.2317962348461151, 0.08431659638881683, 0.09789380431175232, 0.04207255318760872, 0.10233113169670105, 0.09468983858823776, -0.11404743045568466, 0.09076213836669922, -0.001233905553817749, -0.2219977080821991, 0.034782953560352325, 0.042132481932640076, -0.08561461418867111, -0.045762185007333755, -0.07379499822854996, -0.04540342465043068, -0.11874580383300781, -0.015607565641403198, 0.001862905453890562, 0.02020183391869068, 0.025861665606498718, -0.018196340650320053, 0.08940298110246658, 0.2381538450717926, -0.1939868927001953, 0.06258569657802582, 0.021192889660596848, -0.025322336703538895, 0.05135256052017212, 0.01479258295148611, 0.22676703333854675, -0.07561000436544418, 0.09913503378629684, 0.15763233602046967, 0.18828794360160828, -0.13143131136894226, 0.07341417670249939, -0.0118425153195858, 0.02273789420723915, 0.11202742159366608, 0.014703642576932907, 0.127726212143898, -0.006416697986423969, 0.0981433242559433, 0.09657585620880127, 0.09405362606048584, -0.03555891290307045, 0.009460171684622765, 0.011136713437736034, 0.03751572594046593, -0.10754720866680145, 0.015064412727952003, 0.13399052619934082, 0.06484620273113251, -0.1133945882320404, -0.189480721950531, -0.05987627059221268, 0.0014076493680477142, -0.06933671236038208, -0.09692169725894928, -0.03599817305803299, -0.06962679326534271, -0.015223822556436062, 0.09814314544200897, -0.045086123049259186, -0.015718776732683182, 0.017457265406847, -0.0870860368013382, -0.041061900556087494, -0.0759199932217598, 0.15855193138122559, 0.05287732556462288, -1.0065222966204601e-07, 0.05269970744848251, -0.09892962872982025, -0.08802628517150879, -0.13830921053886414, -0.02719477191567421, -0.11462588608264923, -0.03545845299959183, 0.0078823771327734, -0.13717004656791687, 0.0851822942495346, 0.050252754241228104, 0.1484287679195404, -0.04905606806278229, -0.1619964838027954, -0.050099022686481476, -0.15168365836143494, 0.022505763918161392, 0.02581452764570713, 0.03585490584373474, 0.06298292428255081, 0.004208605736494064, -0.054438516497612, 0.08340197056531906, -0.10197953879833221, 0.0968916118144989, -0.058627255260944366, 0.0702146589756012, 0.11538524925708771, 0.05570662394165993, -0.05619830638170242, 0.09064959734678268, -0.01127675361931324, 0.03539305180311203, 0.10909649729728699, -0.041809942573308945, -0.049292586743831635, -0.047180768102407455, 0.031228255480527878, -0.018768196925520897, 0.12044396251440048, -0.0009257495403289795, -0.14385423064231873, -0.05222306028008461, -0.018349604681134224, 0.026765091344714165, -0.06296198070049286, -0.00342452060431242, -0.04753870517015457, 0.05643276497721672, -0.04997112601995468, -0.029272399842739105, 0.0404081717133522, -0.07727521657943726, -0.11828115582466125, 0.06360270828008652, 0.10175743699073792, -0.12471778690814972, 0.017952628433704376, 0.0006530662067234516, -0.13699951767921448, 0.015092670917510986, -0.07717200368642807, 0.062086012214422226, 0.057013265788555145], "changes": {"1wk": 0.8064549909724368}}, {"text": "Keros Therapeutics Stock Plunges 81% in 3 Months: Here's Why Zacks Equity Research Thu, Jan 23, 2025, 5:13 PM 4 min read In This Article: KROS -2.37% Shares of Keros Therapeutics KROS, a clinical-stage biotech, have plunged 80.9% in the past three months. The massive decline was primarily due to the company\u2019s voluntary decision to halt dosing in the ongoing mid-stage study of its pipeline candidate, cibotercept (KER-012), to treat patients with pulmonary arterial hypertension (PAH), a kind of lung disease. Keros Therapeutics\u2019 decision was based on unexpected adverse pericardial effusion events that were observed during the study's safety review by an independent data monitoring committee (DMC). Cibotercept is an investigational modified ActRIIB fusion protein. The phase II TROPOS\u00a0study is evaluating three doses of cibotercept (1.5 mg/kg, 3 mg/kg and 4.5 mg/kg) in combination with background therapy to treat PAH patients. After consulting with the DMC, Keros Therapeutics initially chose to suspend dosing in the 3 mg/kg and 4.5 mg/kg treatment arms of the TROPOS study while continuing dosing in the 1.5 mg/kg arm. However, earlier this month, the company announced the suspension of dosing in the 1.5 mg/kg and placebo arms as well, following the observation of new adverse pericardial effusion events during an ongoing safety review. In the past year, KROS shares have plunged 79.8% compared with the industry\u2019s 12% decline. Zacks Investment Research Image Source: Zacks Investment Research Keros Therapeutics has informed investigators and certain regulatory authorities, including the FDA, of this decision and is in the process of notifying other relevant regulatory bodies. The TROPOS study is being concluded ahead of schedule, with patients expected to be monitored through their end-of-trial visits. The company still plans to present top-line data from all treatment arms of the mid-stage study in the second quarter of 2025. Other Developmental Programs in KROS\u2019 Pipeline Keros has two other novel investigational candidates in its clinical-stage pipeline, elritercept (KER-050), ActRIIA fusion protein, and KER-065, a selective activin receptor ligand trap. Elritercept is currently being evaluated in two ongoing phase II studies to treat patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) and patients with myelofibrosis. KROS is also gearing up to initiate enrollment in a planned, registrational phase III study of elritercept called RENEW to treat adult patients with transfusion-dependent anemia with very low-, low-, or intermediate-risk MDS. Last month, the company also signed a global licensing agreement with Takeda to advance the development and commercialization of elritercept. Story Continues Keros Therapeutics\u2019 KER-065 is being developed for the treatment of obesity and neuromuscular diseases. Currently, a phase I study is evaluating single and multiple ascending doses of thecandidate in healthy adults. Top-line data is anticipated in the first quarter of 2025. Upon completing this early-stage study, KROS plans to initiate a proof-of-concept study of KER-065 in obese patients. Keros Therapeutics, Inc. Price and Consensus Keros Therapeutics, Inc. Price and Consensus Keros Therapeutics, Inc. price-consensus-chart | Keros Therapeutics, Inc. Quote KROS\u2019 Zacks Rank & Other Stocks to Consider Keros Therapeutics currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks from the sector are Castle Biosciences CSTL, BioMarin Pharmaceutical BMRN and CytomX Therapeutics CTMX. While CSTL and BMRN currently sporta Zacks Rank #1 (Strong Buy), CTMX carries a Zacks Rank #2 at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 30 days, Castle Biosciences\u2019 earnings estimates for 2024 have increased from 34 cents to 39 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 16.3%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 30 days, estimates for BioMarin Pharmaceutical\u2019s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have decreased from $4.05 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 11.9%. BMRN\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%. In the past 30 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 22.4%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report Keros Therapeutics, Inc. (KROS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CTMX", "date": "2025-01-23T14:13:00+00:00", "sentiment": {"score": -0.9078345000743866, "confidence": 0.9244498014450073, "probabilities": {"positive": 0.016615301370620728, "negative": 0.9244498014450073, "neutral": 0.05893493443727493}}, "embedding": [-0.05887255072593689, -0.09179868549108505, 0.0006085075438022614, -0.10331851243972778, -0.017146263271570206, -0.10313019156455994, -0.09511338919401169, 0.3107947111129761, 0.15389785170555115, 0.1147817000746727, -0.020119085907936096, 0.019200799986720085, -0.08165373653173447, 0.03372814506292343, -0.07036685198545456, -0.05612838268280029, 0.04669757932424545, -0.008446233347058296, -0.1402621865272522, 0.07682973146438599, -0.014030514284968376, -0.07006245106458664, -0.05592545121908188, 0.10419730842113495, -0.04219736158847809, 0.10974876582622528, -0.1148228719830513, -0.0724385604262352, -0.06764238327741623, -0.10677046328783035, 0.027358777821063995, 0.07827722281217575, 0.032724618911743164, -0.00456278957426548, 0.07862067222595215, 0.019933275878429413, -0.17000934481620789, 0.026518188416957855, -0.13471052050590515, -0.07230442762374878, 0.03248227760195732, -0.10153110325336456, -0.13942238688468933, 0.016008783131837845, -0.019494695588946342, 0.009953583590686321, -0.1524604856967926, 0.07552149891853333, 0.05395898595452309, 0.19165603816509247, -0.13362570106983185, -0.20997391641139984, 0.04917789623141289, 0.0791708379983902, -0.11855177581310272, -0.046780653297901154, -0.18389007449150085, -0.028571520000696182, 0.042995091527700424, 0.01726945862174034, -0.09056682884693146, -0.01613347791135311, -0.017936451360583305, 0.0534452348947525, 0.0731002539396286, 0.022797580808401108, 0.13476185500621796, -0.048319198191165924, 0.05027831345796585, 0.03375343605875969, 0.19883011281490326, -0.08598917722702026, 0.03630632162094116, 0.09135626256465912, -0.09947457909584045, 0.1422598510980606, 0.1271177977323532, 0.03391718119382858, 0.06174013763666153, -0.10122747719287872, 0.09797213226556778, 0.09027954936027527, -0.006375850178301334, -0.04099462926387787, -0.07082225382328033, 0.05756591260433197, -0.11550550162792206, 0.0988692045211792, 0.02806752920150757, -0.010973515920341015, 0.14877215027809143, 0.004054456949234009, 0.0630999282002449, -0.024503367021679878, 0.015641160309314728, 0.05832301080226898, -0.13029815256595612, 0.07224268466234207, 0.04106342792510986, 0.012242432683706284, 0.03707639127969742, 0.07296600937843323, -0.06791957467794418, -0.07020208239555359, -0.05517684668302536, -0.17165714502334595, 0.05545719340443611, -0.11248618364334106, 0.011548146605491638, 0.10041224956512451, -0.07858723402023315, 0.014787337742745876, 0.06929364055395126, -0.05610983446240425, 0.09597856551408768, 0.1747991442680359, 0.02223227545619011, 0.0411519929766655, 0.2094843089580536, 0.06957684457302094, 0.030609264969825745, -0.06621506810188293, 0.03205972909927368, -0.06991342455148697, -0.008239053189754486, 0.06933251023292542, -0.08336851000785828, 7.894426103554597e-33, 0.03583436459302902, -0.045379720628261566, 0.10291724652051926, -0.036423537880182266, -0.015488345175981522, -0.09195999801158905, -0.0388912595808506, -0.05825745686888695, -0.08894019573926926, -0.14678922295570374, -0.13291555643081665, -0.012605350464582443, 0.03962402045726776, 0.007914424873888493, -0.11578626930713654, -0.10738053917884827, -0.05641785264015198, 0.12524981796741486, 0.01784096285700798, 0.023128356784582138, 0.030001893639564514, -0.07696395367383957, -0.05233094096183777, 0.07212207466363907, -0.05711596831679344, 0.09213677048683167, -0.11677460372447968, 0.05319968983530998, -0.08203896135091782, 0.04525139555335045, -0.10821172595024109, 0.08547072857618332, -0.023784000426530838, -0.07269294559955597, -0.13139435648918152, -0.0643421933054924, -0.068524070084095, -0.021910782903432846, 0.013927179388701916, 0.11768838763237, -0.06066828966140747, 0.0524040088057518, -0.13868531584739685, -0.11760932207107544, 0.06859038025140762, -0.13517196476459503, -0.16380590200424194, -0.04348527640104294, -0.030430540442466736, -0.04885707423090935, 0.040768202394247055, -0.08764338493347168, 0.12761741876602173, -0.04239910840988159, -0.0017078351229429245, 0.0983881801366806, -0.06970398873090744, -0.15049508213996887, 0.05226007103919983, 0.05983718857169151, 0.016596337780356407, 0.17045408487319946, 0.013764360919594765, 0.07844295352697372, -0.08088777959346771, 0.044085219502449036, -0.10437309741973877, -0.039229728281497955, -0.10365825891494751, 0.10053925216197968, -0.11815863847732544, -0.029787471517920494, 0.13029566407203674, -0.07374903559684753, 0.11684281378984451, -0.12002049386501312, -0.05118285119533539, 0.17858171463012695, -0.0517214760184288, 0.11915622651576996, 0.032879747450351715, -0.0160621777176857, -0.005433402024209499, 0.08365093171596527, 0.03833191096782684, -0.034006062895059586, -0.016442378982901573, 0.06664906442165375, -0.09887351095676422, -0.05700596421957016, 0.08893714845180511, -0.12154915928840637, -0.13548868894577026, 0.1522584855556488, 0.05207916721701622, -1.0272264565539892e-32, -0.00290659349411726, 0.04763311892747879, 0.0066963424906134605, -0.010559525340795517, 0.04013910889625549, 0.19945617020130157, 0.11166051030158997, -0.05486009269952774, 0.16154834628105164, -0.03727928549051285, 0.06707245111465454, 0.04861721768975258, -0.01600601151585579, -0.05449744686484337, -0.06057038903236389, 0.06854403018951416, -0.07880379259586334, -0.026830745860934258, -0.05388930067420006, -0.018827645108103752, 0.04879070073366165, 0.03504689037799835, -0.0449192151427269, 0.1428270787000656, 0.052133284509181976, 0.004162610042840242, -0.0011626314371824265, 0.06580200791358948, 0.06543145328760147, -0.10225431621074677, 0.033478911966085434, -0.009823527187108994, -0.20756149291992188, 0.09811599552631378, 0.04892991483211517, -0.08972807228565216, -0.06822944432497025, 0.02478267438709736, 0.02754349447786808, -0.192193865776062, 0.071992427110672, 0.12744444608688354, 0.09004006534814835, -0.013676505535840988, 0.000974562019109726, 0.01830149069428444, 0.1767350733280182, -0.19096270203590393, 0.12355827540159225, -0.1400061547756195, -0.06561973690986633, 0.045606132596731186, -0.0666014552116394, 0.15925787389278412, 0.025062482804059982, 0.03608269616961479, 0.03566238656640053, 0.036777690052986145, -0.18965575098991394, 0.10338348895311356, 0.017972471192479134, 0.007016241084784269, -0.033454231917858124, -0.08220575749874115, 0.06737446784973145, 0.01886560581624508, 0.053973376750946045, 0.019275669008493423, 0.11282412707805634, -0.07721655070781708, -0.08575406670570374, -0.04491962119936943, 0.011523245833814144, -0.09530775249004364, 0.08343154937028885, 0.046247366815805435, -0.02872382663190365, -0.13840973377227783, -0.09635752439498901, -0.04158097505569458, -0.057776063680648804, -0.0657300129532814, -0.08082123845815659, 0.04567398503422737, 0.021137660369277, 0.1088525578379631, 0.022638626396656036, -0.041457854211330414, 0.016502171754837036, -0.030330294743180275, -0.06526678800582886, -0.09187397360801697, -0.10832879692316055, 0.12238189578056335, 0.0396486334502697, -1.0074913348034897e-07, 0.14722734689712524, -0.03486698865890503, 0.023902539163827896, 0.010059555992484093, 0.05182616040110588, -0.08026251941919327, 0.013650653883814812, 0.05503110587596893, -0.04659776762127876, 0.09866504371166229, 0.08482110500335693, 0.12206974625587463, -0.0468263179063797, -0.0018472044030204415, 0.010177540592849255, -0.08556872606277466, -0.016795216128230095, 0.08692987263202667, 0.02999788522720337, 0.011628599837422371, 0.006611539516597986, -0.0832366943359375, 0.05900564044713974, -0.09866657853126526, 0.015439148992300034, 0.010558811016380787, 0.0733298510313034, 0.07358264923095703, 0.012740095146000385, 0.02864108793437481, -0.07800313830375671, -0.05215899273753166, -0.042741525918245316, 0.04978266358375549, 0.009602983482182026, -0.08421467244625092, 0.03855764865875244, 0.07739855349063873, -0.004982484970241785, 0.1796431839466095, -0.020939843729138374, 0.011617975309491158, 0.005426622927188873, 0.05348770692944527, -0.05379154160618782, 0.010758135467767715, -0.0759378969669342, -0.030056685209274292, 0.03958302363753319, -0.08141857385635376, 0.04501661658287048, 0.0006824880838394165, -0.07058639079332352, 0.03621387854218483, -0.038094986230134964, 0.11917346715927124, -0.09668143093585968, -0.11541677266359329, -0.056951701641082764, -0.08933670818805695, 0.128561332821846, -0.12652331590652466, 0.020491888746619225, 0.07689718157052994], "changes": {"1wk": -5.529951575344634}}, {"text": "AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer Zacks Equity Research Mon, Jan 20, 2025, 10:05 PM 4 min read In This Article: AZN -1.27% CTMX -1.16% AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC),\u00a0datopotamab deruxtecan (or Dato-DXd), in patients with a certain type of breast cancer. The drug, developed in partnership with Japan-based Daiichi Sankyo, will be marketed under the brand name Datroway. Post the FDA\u2019s approval, the ADC drug is approved to treat unresectable or metastatic HR-positive, HER2-negative breast cancer in adult patients who have received prior endocrine-based therapy and chemotherapy. This approval came just a few weeks after Daiichi secured approval for the drug for a similar indication in Japan. The approvals in the United States and Japan are based on data from the phase III TROPION-Breast01 study, which showed that treatment with Datroway significantly reduced the risk of disease progression or death by 37% compared to the investigator\u2019s choice of chemotherapy in the above indication. Per AstraZeneca, Datroway is part of a select group of therapies that could achieve peak annual sales of at least $5 billion. These medicines are part of management\u2019s ambitious growth strategy to achieve $80 billion in annual revenues by 2030. AZN Stock Performance In the past year, AstraZeneca\u2019s shares have lost nearly 1% compared with the industry\u2019s 5.4% decline. Zacks Investment Research Image Source: Zacks Investment Research Recent Developments With AZN\u2019s Datroway Datroway is the second ADC drug developed under the AstraZeneca-Daiichi partnership, the first being the blockbuster Enhertu. Per the terms of the partnership, both companies are jointly responsible for developing and marketing the drugs worldwide, except Japan, where Daiichi maintains exclusive rights for both. Daiichi is also responsible for the manufacturing and supply of both Enhertu and Datroway. AZN and partner Daiichi are currently evaluating Datroway in an extensive clinical development program as both a monotherapy and in combination with other drugs across multiple cancer indications, including breast and lung cancers. This includes seven late-stage programs across lung cancer indications and five in breast cancer. Last week, management announced that a regulatory filing was granted priority review by the FDA, seeking approval for Datroway to treat adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). A final decision is expected in third-quarter 2025. The drug was granted breakthrough therapy designation by the FDA in this indication last month. ADCs like Enhertu and Datroway are being considered disruptive innovations in the pharmaceutical industry as these will enable better treatment of cancer by harnessing the targeting power of antibodies to deliver cytotoxic molecule drugs to tumors. Story Continues FDA Expands Label for AZN\u2019s Cancer Drug Calquence In a separate press release, AstraZeneca announced that the FDA has expanded the label of its blockbuster cancer drug Calquence in 2017 for the first-line treatment of mantle cell lymphoma (MCL). The drug is now approved in combination with chemoimmunotherapy (bendamustine and rituximab) to treat adult patients with previously untreated MCL who are ineligible for autologous hematopoietic stem cell transplantation. The above decision also converts the accelerated approval granted to Calquence in 2017 for adult patients with MCL treated with at least one prior therapy to a full one. The FDA\u2019s approval is based on data from the phase III ECHO study, which showed that treatment with Calquence-chemoimmunotherapy combo reduced the risk of disease progression or death by 27% compared to chemoimmunotherapy alone in the above indication. AZN\u2019s Zacks Rank AstraZeneca currently carries a Zacks Rank #3 (Hold). AstraZeneca PLC Price AstraZeneca PLC Price AstraZeneca PLC price | AstraZeneca PLC Quote Key Picks Among Biotech Stocks Some better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and Erasca ERAS. While CSTL and CTMX sport a Zacks Rank #1 (Strong Buy) each at present, ERAS carries a Zacks Rank #2 (Buy). You can see the complete list of today\u2019s Zacks #1 Rank stocks here . Bottom-line estimates for Castle Biosciences have improved from a loss of 8 cents per share to earnings of 34 cents for 2024 in the past 60 days. During the same timeframe, loss per share estimates for 2025 have narrowed from $1.88 to $1.84. In the past year, shares of Castle Biosciences have surged 26%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 60 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have narrowed from 13 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 46 cents to 35 cents during the same timeframe. CTMX\u2019s shares have lost 49% in the past year. CytomX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. In the past 60 days, estimates for Erasca\u2019s 2024 loss per share have improved from 76 cents to 73 cents. Estimates for 2025 loss per share have narrowed from 64 cents to 61 cents during the same timeframe. In the past year, Erasca\u2019s shares have risen nearly 6%. ERAS\u2019 earnings beat estimates in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average negative surprise of 7.04%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report Erasca, Inc. (ERAS) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CTMX", "date": "2025-01-20T19:05:00+00:00", "sentiment": {"score": 0.40785107016563416, "confidence": 0.5455036163330078, "probabilities": {"positive": 0.5455036163330078, "negative": 0.13765254616737366, "neutral": 0.3168438673019409}}, "embedding": [-0.0673837885260582, -0.13331715762615204, -0.19746586680412292, -0.009789003059267998, -0.014750692993402481, -0.14060063660144806, 0.021439213305711746, 0.23938149213790894, 0.08594506233930588, -0.02637488767504692, -0.10452829301357269, 0.13596013188362122, 0.03532200679183006, 0.08820480108261108, -0.024309774860739708, 0.05483701080083847, 0.058272361755371094, -0.022151969373226166, -0.067376509308815, 0.09345643222332001, -0.04399959370493889, 0.004840923473238945, 0.14537516236305237, 0.13463804125785828, 0.012223274447023869, -0.08165924996137619, -0.056660547852516174, 0.033040791749954224, -0.16156280040740967, -0.0891212746500969, 0.07070201635360718, 0.052459716796875, 0.04495563358068466, -0.1134941503405571, -0.047462098300457, -0.05375619977712631, -0.07801986485719681, 0.06321363896131516, -0.06288278847932816, -0.10944390296936035, 0.004340372048318386, -0.005205783061683178, -0.15737757086753845, -0.003395579755306244, 0.021922487765550613, -0.2603553235530853, -0.15192343294620514, 0.013647694140672684, 0.09988297522068024, 0.17295719683170319, -0.14868679642677307, -0.11863179504871368, -0.020701520144939423, 0.15084972977638245, -0.11035958677530289, -0.08533132076263428, -0.11441650986671448, 0.009974159300327301, -0.07472948729991913, 0.06175871193408966, -0.031725648790597916, -0.050698429346084595, -0.06206995248794556, 0.007552430033683777, 0.09241670370101929, 0.02936156466603279, -0.04069247096776962, 0.022115139290690422, -0.02260196954011917, 0.06094259023666382, 0.08350174129009247, -0.0274568572640419, 0.15337780117988586, 0.11404776573181152, -0.11458379030227661, 0.033585432916879654, 0.15582504868507385, 0.14485880732536316, 0.11612454056739807, -0.11253072321414948, 0.10300233960151672, 0.06736981868743896, 0.08534029126167297, 0.03755263239145279, 0.016015103086829185, 0.08167416602373123, -0.004145435988903046, 0.12687335908412933, 0.1038912758231163, 0.07218079268932343, 0.12390108406543732, 0.1826431304216385, 0.017783770337700844, 0.0056688785552978516, 0.017248136922717094, -0.017251109704375267, -0.022193701937794685, 0.1351151317358017, 0.05374074727296829, -0.0037976987659931183, 0.05643920600414276, -0.007449357770383358, -0.1751174032688141, -0.09319118410348892, 0.04490121454000473, -0.0062203723937273026, 0.10890151560306549, -0.19683003425598145, 0.05833176523447037, 0.0838049054145813, -0.14376962184906006, -0.051979370415210724, -0.04367708042263985, -0.0416283905506134, -0.17951393127441406, 0.17687226831912994, -0.10556498169898987, -0.02593062072992325, 0.07692405581474304, -0.12549057602882385, 0.016740981489419937, -0.044123440980911255, 0.06836435943841934, -0.11910665035247803, 0.1466754674911499, 0.028908107429742813, -0.11694260686635971, 1.1746037669147458e-32, -0.010425655171275139, 0.06819747388362885, 0.09713080525398254, -0.0042985547333955765, -0.05332174897193909, 0.03273181617259979, -0.017556801438331604, -0.08342186361551285, -0.15207944810390472, -0.10757005214691162, -0.1433601677417755, -0.11564379930496216, -0.08243072032928467, 0.03061819076538086, 0.0023545585572719574, -0.1118016391992569, -0.02555975504219532, 0.1260371059179306, -0.01281992718577385, 0.029327066615223885, 0.07108637690544128, 0.03261808305978775, -0.14621073007583618, 0.0726783275604248, -0.15950334072113037, 0.10525490343570709, -0.09990939497947693, 0.1592581868171692, -0.047938354313373566, 0.09195761382579803, -0.053988486528396606, -0.0637136921286583, 0.013583563268184662, -0.10302865505218506, -0.04692074656486511, -0.13769836723804474, -0.11782388389110565, -0.05185920000076294, 0.0823645293712616, 0.10446980595588684, -0.004913066513836384, -0.02175590768456459, -0.12836125493049622, 0.045244235545396805, 0.030936449766159058, 0.002041594125330448, -0.09942647814750671, -0.003924247343093157, -0.041351884603500366, -0.006193075329065323, -0.10218599438667297, -0.12342646718025208, -0.08295314013957977, -0.07026969641447067, 0.06752624362707138, -0.0002495194785296917, -0.16310562193393707, -0.0025776056572794914, 0.12868936359882355, 0.19114717841148376, -0.03574856370687485, -0.08810020238161087, -0.08014623820781708, 0.08819496631622314, -0.1455652117729187, 0.18336090445518494, 0.014312109909951687, -0.09323199093341827, -0.061490342020988464, 0.08453039824962616, -0.003871842287480831, -0.07459219545125961, 0.1378832757472992, 0.06333716213703156, 0.11182734370231628, -0.011531476862728596, 0.12760087847709656, 0.08690030127763748, 0.08062301576137543, 0.05502583459019661, -0.01573171280324459, -0.05368503928184509, -0.23781129717826843, 0.17946721613407135, -0.05137965828180313, -0.019646184518933296, -0.03853561729192734, -0.003879792056977749, -0.07686854898929596, -0.0021680693607777357, 0.09031219780445099, -0.0674467459321022, -0.016919221729040146, 0.008479381911456585, 0.08022096753120422, -1.2055008277737434e-32, 0.006761896889656782, 0.16534149646759033, 0.027586227282881737, -0.10241460055112839, -0.10241930186748505, 0.0656772255897522, 0.07843837141990662, -0.06190057471394539, 0.22516684234142303, -0.06379975378513336, 0.013903385028243065, 0.031176146119832993, -0.0777813121676445, -0.037180956453084946, -0.17180350422859192, 0.13559786975383759, 0.13466957211494446, -0.07461193203926086, -0.06423309445381165, -0.04873458296060562, 0.08890832960605621, 0.2012670636177063, -0.05354326218366623, 0.06462951004505157, -0.022526277229189873, 0.043269332498311996, 0.08333264291286469, 0.09728136658668518, 0.15362761914730072, 0.050345417112112045, -0.05779142677783966, 0.025076858699321747, -0.21404966711997986, 0.036819178611040115, -0.12182796001434326, -0.049375779926776886, 0.03831776604056358, -0.20008550584316254, -0.08078859746456146, -0.14180870354175568, -0.022681772708892822, 0.04179273918271065, -0.09848371148109436, -0.012375673279166222, 0.010140549391508102, 0.030540969222784042, -0.028662430122494698, 0.12559451162815094, 0.16669979691505432, -0.0847361832857132, 0.0046670278534293175, 0.004104176536202431, 0.06707848608493805, 0.04324383661150932, -0.0519116185605526, -0.07256004214286804, 0.08306866139173508, 0.014194948598742485, -0.05028083175420761, 0.07103188335895538, 0.049475230276584625, 0.06181721389293671, 0.0324123352766037, 0.002371187787503004, -0.054469939321279526, 0.18835757672786713, 0.1276649385690689, -0.03497125580906868, 0.042198218405246735, -0.10495959967374802, -0.06901619583368301, -0.006835803389549255, -0.040457841008901596, -0.008946039713919163, -0.0930178314447403, 0.13244479894638062, -0.04096170514822006, -0.1860491931438446, -0.0555393323302269, 0.031518448144197464, -0.059809938073158264, -0.004518177360296249, -0.0337357334792614, -0.12405466288328171, 0.0006984695792198181, 0.1469668298959732, -0.09066138416528702, -0.03932740166783333, -0.017471183091402054, 0.07343728095293045, -0.07193408906459808, -0.10307558625936508, -0.05368439108133316, 0.13931262493133545, 0.006046793423593044, -1.0097208757997578e-07, 0.12716037034988403, -0.17145569622516632, 0.11798453330993652, -0.14505618810653687, 0.03481945022940636, -0.039658356457948685, -0.08949970453977585, 0.08512035012245178, 0.11705704778432846, 0.13002225756645203, -0.006906623020768166, 0.2672244608402252, -0.13322241604328156, 0.0030625825747847557, -0.12453708052635193, 0.006798502057790756, 0.12336868047714233, 0.04937759414315224, -0.02360810711979866, -0.050775688141584396, -0.11250239610671997, -0.0014664307236671448, -0.004705492872744799, -0.15552368760108948, 0.08359323441982269, -0.004616139456629753, 0.004303782247006893, 0.12129293382167816, 0.05340104550123215, -0.02832590416073799, 0.05594126135110855, -0.04502379894256592, 0.18895025551319122, -0.029223496094346046, 0.005276167765259743, -0.0742727592587471, 0.04778440669178963, 0.025321735069155693, 0.01852264069020748, 0.06063127517700195, 0.04956745356321335, 0.014650758355855942, 0.025505609810352325, 0.02006460353732109, -0.09926468133926392, 0.016034917905926704, -0.06152504310011864, -0.028365865349769592, 0.061433710157871246, -0.09651704132556915, 0.07978513836860657, -0.09344004094600677, 0.01802496239542961, -0.15253010392189026, -0.057841841131448746, 0.11612283438444138, -0.08335898816585541, -0.10779015719890594, 0.04165586829185486, 0.03745073452591896, 0.060765787959098816, -0.1735944151878357, 0.20675835013389587, 0.026316888630390167], "changes": {"1wk": -0.229618170999637}}, {"text": "Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer Zacks Equity Research Mon, Jan 20, 2025, 5:18 PM 3 min read In This Article: AMGN +1.21% Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR antibody, Vectibix (panitumumab), for treating KRAS G12C-mutated metastatic colorectal cancer (mCRC). The regulatory body approved Lumakras plus Vectibix for treating KRAS G12C-mutated mCRC in adult patients who have previously received fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Lumakras is presently approved for treating advanced or metastatic non-small cell lung cancer (NSCLC). The drug was approved in the United States in May 2021 and in the EU (marketed as Lumykras) in January 2022. In the past year, shares of Amgen have dropped 12.2% compared with the industry\u2019s decline of 14.1%. Zacks Investment Research Image Source: Zacks Investment Research Latest Nod Based on AMGN's CodeBreaK 300 Study Lumakras\u2019 approval for the mCRC indication was based on data from the phase III CodeBreaK 300 study, which evaluated Lumakras plus Vectibix versus the investigator's choice of therapy in KRAS G12C\u2013mutated mCRC. Data from the CodeBreaK 300 study showed that treatment with Lumakras plus Vectibix led to superior progression-free survival (PFS) versus the investigated standard-of-care (SOC) in KRAS G12C-mutated mCRC \u2013 the study\u2019s primary endpoint. The study evaluated two different doses of Lumakras (960 mg daily or 240 mg daily) in combination with Vectibix versus the investigator's choice of SOC (trifluridine and tipiracil or regorafenib) in patients with chemorefractory KRAS G12C-mutated mCRC. Per management, the combo of Lumakras plus Vectibix is now the first and only targeted treatment combination for chemorefractory KRAS G12C-mutated mCRC to demonstrate superior PFS versus the investigated SOC. Data from the CodeBreaK 300 study also showed that treatment with Lumakras plus Vectibix demonstrated favorable overall survival and overall response rate in treating KRAS G12C-mutated mCRC \u2013 the study's key secondary endpoints. More Updates on AMGN's Lumakras In the first nine months of 2024, Lumakras recorded sales worth $265 million, reflecting an increase of 30.5% on a year-over-year basis. Label expansion studies on Lumakras in earlier lines of therapy, which have the potential to significantly expand the currently addressable patient population, are ongoing. Amgen is also evaluating Lumakras in phase I and phase II studies for treating NSCLC as monotherapy and in combination with other therapies. Approval for expanded indications can potentially boost the drug\u2019s sales in future quarters. AMGN's Zacks Rank & Stocks to Consider Amgen currently carries a Zacks Rank #3 (Hold). Story Continues Some better-ranked stocks in the biotech sector are Voyager Therapeutics, Inc. VYGR, CytomX Therapeutics, Inc. CTMX and Castle Biosciences, Inc. CSTL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 60 days, estimates for Voyager Therapeutics\u2019 loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 32.8%. VYGR\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 120.87%. In the past 60 days, estimates for CytomX Therapeutics\u2019 loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have declined 48.5%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%. In the past 60 days, estimates for Castle Biosciences\u2019 loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged 26%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Voyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CTMX", "date": "2025-01-20T14:18:00+00:00", "sentiment": {"score": -0.6591672673821449, "confidence": 0.7775269746780396, "probabilities": {"positive": 0.11835970729589462, "negative": 0.7775269746780396, "neutral": 0.10411334037780762}}, "embedding": [0.06620663404464722, -0.05381939560174942, -0.07094646245241165, -0.08940127491950989, 0.08190590888261795, -0.12414027750492096, -0.10802017897367477, 0.32096123695373535, 0.1641356199979782, 0.025973264127969742, -0.12855494022369385, 0.14630338549613953, 0.12644624710083008, 0.019093384966254234, -0.02124209702014923, 0.15267981588840485, 0.09773139655590057, 0.10488912463188171, -0.18044818937778473, 0.05381881445646286, 0.07042127102613449, -0.12072785198688507, 0.14280222356319427, 0.05062779784202576, -0.09137438982725143, -0.014180879108607769, -0.032654378563165665, -0.02980509027838707, -0.17768684029579163, -0.009930627420544624, 0.1576623022556305, 0.11306974291801453, 0.10371735692024231, -0.03577890992164612, -0.04460454732179642, -0.10633325576782227, -0.22617509961128235, 0.20928359031677246, -0.20277616381645203, -0.07554945349693298, -0.13010120391845703, 0.0543314665555954, -0.07305167615413666, 0.0632510557770729, 0.05415668338537216, -0.18747378885746002, -0.17361047863960266, -0.0655122846364975, -0.060394421219825745, 0.2835186719894409, -0.061453185975551605, -0.11340590566396713, -0.21433702111244202, 0.2040507197380066, 0.00025995541363954544, -0.129576176404953, -0.2945559620857239, 0.0601525604724884, 0.1389988660812378, 0.01106205116957426, -0.02465628832578659, -0.16340377926826477, 0.04486841708421707, -0.014367073774337769, 0.042040158063173294, 0.08003978431224823, 0.029339665547013283, -0.10524707287549973, -0.05339166149497032, -0.04404667019844055, 0.07919283956289291, -0.018948635086417198, 0.045250751078128815, 0.13455036282539368, -0.10652002692222595, 0.11347294598817825, 0.15502837300300598, 0.15646134316921234, 0.08627104759216309, -0.003515370190143585, -0.012636419385671616, 0.11112866550683975, -0.015477471053600311, -0.025191113352775574, 0.11673179268836975, 0.009783310815691948, -0.09633967280387878, 0.22923091053962708, 0.10637520253658295, -0.0023887939751148224, 0.28730010986328125, 0.07867332547903061, -0.035496875643730164, 0.024735070765018463, 0.07124035060405731, -0.05466651916503906, -0.10257384181022644, 0.10074213147163391, 0.001485956832766533, -0.028007611632347107, 0.06722445785999298, -0.11324867606163025, -0.03398919478058815, -0.0816824808716774, -0.10082123428583145, -0.17759853601455688, 0.04926196485757828, -0.09050387144088745, -0.05467935651540756, 0.03763410076498985, -0.019783148542046547, 0.005946468561887741, 0.05673322081565857, -0.023627687245607376, -0.009816894307732582, 0.2757968306541443, 0.03401663154363632, 0.001553202047944069, 0.18767112493515015, 0.038494858890771866, 0.07933937013149261, -0.015911856666207314, 0.050191882997751236, -0.05232604593038559, 0.17401424050331116, 0.07291039824485779, -0.03025832027196884, 1.5659547828518743e-32, -0.041549794375896454, -0.008491195738315582, 0.05289129167795181, 0.12235534191131592, -0.03601294755935669, -0.09263898432254791, 0.14317600429058075, -0.1353202760219574, -0.18007831275463104, -0.13823726773262024, -0.0833439901471138, 0.1910831332206726, 0.002556375227868557, 0.03554433956742287, -0.116909459233284, -0.01987753063440323, -0.017427414655685425, -0.10574325919151306, -0.12851004302501678, -0.012453450821340084, 0.07596005499362946, 0.043314311653375626, 0.054350338876247406, -0.005456293933093548, -0.0540439710021019, 0.019429132342338562, -0.06695909053087234, 0.06756754964590073, 0.020542927086353302, 0.022797631099820137, -0.10345278680324554, -0.020278172567486763, 0.06073853373527527, 0.007016681134700775, -0.15960824489593506, 0.037457361817359924, -0.11617699265480042, -0.07978921383619308, -0.026889868080615997, -0.009490110911428928, -0.06648512184619904, 0.06587066501379013, -0.1785513162612915, -0.020819779485464096, 0.1126040518283844, -0.11538426578044891, -0.16274577379226685, -0.042623840272426605, -0.09410259127616882, -0.02798169106245041, 0.02572232484817505, -0.09121456742286682, -0.01729286089539528, -0.07456918060779572, -0.03169756382703781, 0.01636640541255474, -0.08265121281147003, 0.001009661704301834, 0.043751310557127, 0.06461542099714279, -0.04462457448244095, -0.014526383019983768, 0.01626153290271759, 0.1756393164396286, -0.008136052638292313, 0.02266126312315464, -0.12667030096054077, 0.03097575157880783, -0.12904292345046997, 0.09473680704832077, 0.012509498745203018, 0.051503196358680725, 0.09962666034698486, 0.07583305984735489, 0.02011096477508545, -0.18138523399829865, 0.12690827250480652, 0.12289927899837494, -0.12034498155117035, 0.22013519704341888, 0.04013554006814957, 0.1123020350933075, -0.1987743079662323, 0.16037249565124512, -0.07299718260765076, -0.11531534045934677, -0.12541469931602478, 0.04920537769794464, 0.0067520965822041035, -0.03474850952625275, 0.0867718905210495, -0.09591609239578247, -0.02207326702773571, 0.20535527169704437, 0.018069962039589882, -1.370627588553138e-32, -0.009157801046967506, 0.05110078305006027, 0.06941952556371689, 0.15032462775707245, 0.03360182046890259, 0.20131051540374756, 0.19709278643131256, -0.08392814546823502, 0.13351643085479736, -0.18978987634181976, 0.07085412740707397, 0.11122766137123108, -0.043740399181842804, -0.035673655569553375, -0.10062876343727112, 0.03316843509674072, 0.005647491663694382, 0.045646436512470245, -0.1447073221206665, -0.015193289145827293, 0.008641387335956097, 0.16807396709918976, -0.008038079366087914, -0.0331670381128788, -0.13918134570121765, 0.11038535088300705, 0.057292792946100235, 0.1118473932147026, 0.018316516652703285, -0.06323175132274628, -0.05493627488613129, 0.08291280269622803, -0.16122762858867645, 0.019087329506874084, 0.020658686757087708, -0.06568564474582672, 0.04519452154636383, -0.11738677322864532, -0.1322733759880066, -0.05730241537094116, 0.05952758342027664, 0.07888583093881607, -0.03967655450105667, -0.01958305388689041, -0.04247193783521652, -0.03371404856443405, 0.1844140589237213, -0.01364986039698124, 0.2006828486919403, -0.17523851990699768, -0.07345795631408691, -0.08212044835090637, -0.10145807266235352, 0.02139003947377205, 0.18681274354457855, 0.0014630397781729698, 0.0405258908867836, -0.006886182352900505, -0.12568938732147217, 0.13526885211467743, -0.09358540922403336, -0.009609315544366837, 0.07639622688293457, -0.15482783317565918, 0.05529598146677017, 0.31074512004852295, 0.1218133419752121, -0.0012537934817373753, 0.06212536245584488, -0.05658110976219177, -0.0542142391204834, -0.08396686613559723, -0.0896778553724289, -0.09630226343870163, 0.028583327308297157, 0.1825210154056549, 0.06644577533006668, -0.017952345311641693, -0.15893787145614624, -0.03168782591819763, 0.0036204068455845118, -0.12496067583560944, -0.07247531414031982, -0.06180442497134209, 0.06544419378042221, 0.10344785451889038, -0.05674882233142853, -0.015541750937700272, 0.09378863126039505, -0.05739874392747879, -0.1101643294095993, -0.11459329724311829, -0.01895035244524479, 0.10107947140932083, 0.056073665618896484, -1.0030059627297305e-07, 0.020435981452465057, -0.12710891664028168, -0.0075704362243413925, -0.04853392392396927, 0.04196150600910187, 0.0360359326004982, 0.02556021697819233, 0.017317160964012146, -0.08581309020519257, 0.13405266404151917, 0.11088840663433075, 0.1090952605009079, -0.10625386983156204, -0.05376751720905304, -0.048013292253017426, 0.0005214978009462357, 0.05300752446055412, 0.014941816218197346, 0.01830209605395794, 0.04372129961848259, -0.15898865461349487, -0.034457772970199585, 0.0697445198893547, -0.09786763787269592, -0.04275428131222725, -0.08043850213289261, -0.07025037705898285, 0.08152912557125092, 0.0734967291355133, -0.061882611364126205, -0.0022057355381548405, -0.06850869953632355, 0.056585147976875305, -0.0073165250942111015, -0.0980544462800026, -0.1003054678440094, 0.08591750264167786, 0.12127655744552612, 0.12861530482769012, 0.18187056481838226, 0.10910184681415558, 0.02733098715543747, -0.010171877220273018, -0.014366546645760536, -0.1731400489807129, -0.01096036285161972, -0.1580137014389038, -0.0495896190404892, -0.08966945856809616, -0.07636687159538269, 0.013660309836268425, -0.05612075328826904, -0.05915302038192749, -0.14295899868011475, -0.11178050190210342, 0.07034458220005035, 0.009284697473049164, -0.004271244164556265, 0.05134133622050285, -0.14608989655971527, 0.0069759078323841095, -0.2276521921157837, 0.036773502826690674, 0.03886024281382561], "changes": {"1wk": 2.2962090829678186}}, {"text": "Is it a Good Idea to Invest in Stoke Therapeutics Stock Now? Zacks Equity Research Fri, Jan 17, 2025, 6:28 PM 3 min read In This Article: STOK +0.35% Massachusett-based Stoke Therapeutics STOK is making rapid progress with the development of zorevunersen (STK-001), its investigational candidate for treating Dravet syndrome, a severe and progressive genetic epilepsy. Zorevunersen is a novel proprietary antisense oligonucleotide with the potential to become the first disease-modifying therapy to address the genetic cause of Dravet syndrome. The FDA granted a Breakthrough Therapy designation to zorevunersen for treating Dravet syndrome in December 2024. In the past year, shares of Stoke Therapeutics have rallied 94.7% against the industry\u2019s decline of 13.6%. Zacks Investment Research Image Source: Zacks Investment Research Successful Development of Zorevunersen Holds Key for STOK Earlier this month, STOK achieved alignment from various regulatory agencies across the world related to the design of the phase III EMPEROR study on zorevunersen in Dravet syndrome. Following discussions with the FDA, the European Medicines Agency and Japan\u2019s Pharmaceuticals and Medical Devices Agency, the company decided on the protocol for the EMPEROR study. Per the company, the randomized, double-blind EMPEROR study will evaluate two loading doses of zorevunersen (70mg) followed by two maintenance doses of 45mg for a period of 52 weeks compared with sham in children and adolescents aged two to less than 18 years with Dravet syndrome. The phase III study, which will be conducted in the United States, the United Kingdom, Europe and Japan, is expected to begin in mid-2025. Management remains focused on developing zorevunersen as potentially the first disease-modifying medicine for treating Dravet syndrome. Besides zorevunersen, STOK is also looking to develop another candidate, STK-002, for the treatment of autosomal dominant optic atrophy. STOK's Zacks Rank & Rising Estimates Stoke Therapeutics currently has a Zacks Rank #2 (Buy). In the past 60 days, estimates for STOK\u2019s 2025 loss per share have narrowed from $2.49 to $2.43. STOK put up a strong performance in 2024. Positive regulatory updates and the successful development of zorevunersen should help the stock gain further in 2025. Other Stocks to Consider Some other top-ranked stocks in the biotech sector are Voyager Therapeutics, Inc. VYGR, CytomX Therapeutics, Inc. CTMX and Castle Biosciences, Inc. CSTL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 60 days, estimates for Voyager Therapeutics\u2019 loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 30.6%. Story Continues VYGR\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 120.87%. In the past 60 days, estimates for CytomX Therapeutics\u2019 loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have decreased 49.5%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%. In the past 60 days, estimates for Castle Biosciences\u2019 loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged 28.4%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Voyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Stoke Therapeutics, Inc. (STOK) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CTMX", "date": "2025-01-17T15:28:00+00:00", "sentiment": {"score": 0.7254004599526525, "confidence": 0.7348681688308716, "probabilities": {"positive": 0.7348681688308716, "negative": 0.009467708878219128, "neutral": 0.255664199590683}}, "embedding": [-0.10364526510238647, -0.019293610006570816, -0.08569057285785675, 0.04301551729440689, -0.07043510675430298, -0.10611408948898315, -0.08369100093841553, 0.3867727518081665, 0.09397311508655548, 0.03288847580552101, -0.058212876319885254, 0.10397392511367798, -9.707454591989517e-05, 0.05654648691415787, -0.07696770131587982, -0.004542437847703695, -0.010471174493432045, 0.023767253383994102, -0.04176298528909683, 0.04630102962255478, 0.010120600461959839, -0.037716057151556015, 0.09735359251499176, -0.015217511914670467, -0.046689581125974655, 0.02535090036690235, -0.11014366149902344, -0.03366374224424362, -0.033810652792453766, -0.03229527175426483, 0.010317636653780937, 0.08307746797800064, -0.0049566300585865974, -0.10209808498620987, -0.07920068502426147, -0.0446135476231575, -0.14007797837257385, -0.05216391384601593, -0.15140113234519958, -0.018708420917391777, 0.11137180030345917, -0.05113748461008072, -0.12208205461502075, -0.006269302684813738, -0.05257145315408707, -0.05268985033035278, -0.04728510230779648, 0.08963390439748764, -0.11289286613464355, 0.1382743865251541, -0.13749778270721436, -0.21336135268211365, 0.06099448353052139, 0.12278633564710617, -0.03742184489965439, 0.01871625892817974, -0.21052083373069763, 0.042435575276613235, -0.050662264227867126, 0.0199417881667614, -0.03286802023649216, 0.015884913504123688, -0.06403613090515137, -0.10057531297206879, 0.11176276206970215, 0.06727057695388794, -0.00343081122264266, -0.03627247363328934, 0.033720869570970535, -0.056649331003427505, 0.10753439366817474, -0.08101853728294373, 0.10695144534111023, 0.10282514244318008, -0.08943953365087509, 0.15131527185440063, 0.16954419016838074, 0.09234004467725754, 0.08002924919128418, -0.19037944078445435, 0.1390138864517212, 0.042851150035858154, 0.05856823921203613, 0.012457344681024551, 0.05676940456032753, 0.12772387266159058, -0.07121248543262482, 0.13784514367580414, 0.022501926869153976, 0.12414894253015518, 0.14979612827301025, 0.0024237986654043198, -0.017448125407099724, 0.06819426268339157, 0.020093953236937523, 0.0660480409860611, -0.03535175696015358, -0.006266036070883274, -0.08034909516572952, 0.02753898873925209, 0.06049089506268501, 0.020594822242856026, 0.045773670077323914, -0.039818234741687775, -0.06805212050676346, -0.009904510341584682, 0.043241433799266815, -0.13788524270057678, -0.0729980617761612, -0.02890521101653576, -0.11033947765827179, 0.026202796027064323, 0.020936040207743645, -0.09103305637836456, -0.07428137958049774, 0.13099537789821625, -0.05342775955796242, 0.04170840233564377, 0.20394286513328552, 0.03141455352306366, 0.12846745550632477, -0.00975490640848875, -0.05048094689846039, -0.13486136496067047, 0.026223856955766678, 0.05804392322897911, -0.12012983113527298, 1.143563148808154e-32, -0.17687475681304932, 0.08989156037569046, -0.009646284393966198, 0.024720514193177223, -0.14594396948814392, 0.05737551301717758, 0.07299545407295227, 0.0679868683218956, -0.04128614068031311, -0.20286983251571655, -0.1517854928970337, -0.1396823227405548, -0.05168106406927109, 0.10310590267181396, -0.08224016427993774, -0.14696136116981506, 0.07223908603191376, 0.12655594944953918, 0.025927625596523285, -0.04254082217812538, 0.0911245346069336, -0.04255804419517517, -0.09566923975944519, -0.0029530744068324566, -0.014858672395348549, 0.039766162633895874, -0.14563384652137756, -0.02960246056318283, 0.05965975299477577, 0.07158975303173065, -0.018747996538877487, -0.0006976239383220673, -0.07521975040435791, -0.18761470913887024, -0.06537525355815887, -0.005844801664352417, 0.005204592831432819, -0.1133299469947815, 0.027450628578662872, -0.00762223219498992, -0.02157207578420639, 0.04153646156191826, -0.17895612120628357, 0.05872758477926254, 0.05445469915866852, -0.006919845938682556, -0.09773442149162292, -0.07037428021430969, -0.03137747943401337, -0.13658130168914795, -0.044086311012506485, -0.04542418196797371, -0.1109168604016304, -0.014174606651067734, -0.03837481141090393, 0.09183762967586517, -0.1398358792066574, -0.12627504765987396, 0.012065739370882511, 0.050382427871227264, 0.10897114127874374, 0.11846619844436646, -0.054957516491413116, 0.06543663144111633, -0.03492650389671326, 0.10264965146780014, -0.027292931452393532, -0.10147882997989655, -0.23696471750736237, 0.08912096917629242, -0.02781667187809944, -0.0672016590833664, 0.1318170130252838, -0.02832241915166378, 0.07264983654022217, -0.07386650890111923, 0.07676264643669128, 0.2326912134885788, 0.09872621297836304, -0.005689291283488274, 0.0222439244389534, 0.04175925999879837, -0.1280154138803482, 0.03542916476726532, 0.046970851719379425, 0.005365571938455105, 0.03577995300292969, 0.034079160541296005, -0.08040642738342285, 0.030260033905506134, 0.13143950700759888, -0.10467115789651871, -0.053443681448698044, 0.04055122658610344, 0.01968352496623993, -1.1874415611252668e-32, -0.18631747364997864, 0.09329111874103546, 0.018962159752845764, -0.026075327768921852, -0.012998207472264767, 0.0839119404554367, 0.04029223322868347, -0.04317168891429901, 0.03991929814219475, -0.15810266137123108, 0.10025463998317719, 0.054189808666706085, -0.02685283124446869, -0.040521711111068726, -0.12229028344154358, 0.07591958343982697, -0.13391897082328796, -0.0031529534608125687, 0.06071756035089493, 0.02460526116192341, 0.18036045134067535, 0.1167180985212326, -0.022599579766392708, 0.1307860165834427, 0.07546937465667725, -0.025726990774273872, 0.09309642016887665, 0.13028666377067566, 0.08032548427581787, 0.04404103755950928, -0.019933460280299187, -0.004927520640194416, -0.20990169048309326, 0.0008480576798319817, -0.06547047197818756, -0.005631700158119202, 0.02292587235569954, -0.10572303831577301, -0.05833014100790024, -0.18782559037208557, 0.034211039543151855, -0.026787709444761276, 0.011431105434894562, -0.01929321140050888, 0.09610255062580109, 0.11443831771612167, 0.017593614757061005, 0.04341099411249161, 0.20320266485214233, -0.01911737583577633, 0.04536449909210205, 0.14625607430934906, -0.034419700503349304, 0.03302715718746185, -0.0024188398383557796, -0.034902654588222504, 0.08902299404144287, -0.11286437511444092, -0.16538134217262268, 0.024090833961963654, -0.055843133479356766, 0.009754108265042305, -0.06796327978372574, -0.025052405893802643, 0.10472388565540314, -0.04253830388188362, 0.128467857837677, 0.05398639664053917, 0.17567992210388184, -0.1323436051607132, -0.02986481413245201, -0.0013763057067990303, -0.006362518295645714, -0.16187988221645355, -0.012324489653110504, 0.1426912248134613, 0.018616557121276855, -0.09291492402553558, -0.0606653057038784, -0.05345568805932999, -0.05899246782064438, 0.008567790500819683, 0.07345499843358994, 0.034624531865119934, 0.0003998633474111557, 0.03228547424077988, 0.05149097740650177, -0.04248616471886635, 0.008360642939805984, 0.06041380763053894, -0.16266731917858124, -0.10773435235023499, -0.14043259620666504, 0.04757121950387955, 0.09236812591552734, -1.0122187177330488e-07, 0.13864344358444214, -0.09215310215950012, 0.03838767856359482, -0.01724281907081604, 0.03632292151451111, -0.10886633396148682, -0.13806553184986115, 0.043985165655612946, -0.07984976470470428, 0.1417829692363739, -0.03999631851911545, 0.13491040468215942, -0.03331349417567253, -0.01743234135210514, -0.08058510720729828, -0.07933279871940613, 0.03120899572968483, 0.13053950667381287, -0.035011157393455505, -0.013009297661483288, 0.032004132866859436, 0.0343310609459877, 0.13028651475906372, -0.09636508673429489, 0.09021548181772232, -0.00915430299937725, 0.05806907266378403, 0.03445665165781975, -0.009110821411013603, -0.05928691476583481, 0.10836479067802429, -0.02699490264058113, 0.14545410871505737, 0.08498747646808624, -0.0343029722571373, -0.16610601544380188, -0.041779521852731705, 0.11544963717460632, 0.03866984695196152, 0.09258896857500076, 0.03941664099693298, -0.0095379538834095, 0.10908452421426773, 0.09298613667488098, -0.08145958185195923, -0.059386804699897766, -0.005735354498028755, -0.0465678907930851, 0.0841161236166954, -0.08945482969284058, -0.014918581582605839, 0.023660853505134583, -0.01238313689827919, -0.09928963333368301, 0.0026599164120852947, 0.10594900697469711, -0.042603202164173126, 0.023886697366833687, -0.16850002110004425, -0.04606245830655098, 0.06907067447900772, -0.11682115495204926, 0.03634677082300186, 0.09772087633609772], "changes": {"1wk": 6.071428647454907}}, {"text": "IBRX Stock Soars on Completing Filing for Cancer Therapy in EU & UK Zacks Equity Research Fri, Jan 17, 2025, 5:35 PM 4 min read ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in the EU and the United Kingdom for\u00a0Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Gu\u00e9rin (BCG) to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients with carcinoma in situ (CIS), with or without papillary tumors. Acceptance of ImmunityBio\u2019s applications seeking approval of the combo therapy by respective regulatory bodies in the EU and the United Kingdom for review is expected to be completed by the fourth quarter of 2025, with final decisions anticipated by 2026. A nod from the European Medicine Agency would make the Anktiva/BCG combo eligible for commercialization in all 27 EU counties, as well as Iceland,\u00a0Norway and\u00a0Liechtenstein. Please note that Anktiva, in combination with BCG, received FDA approval in April 2024 to treat the same indication in the United States. Per ImmunityBio, the U.S. launch of the combo therapy for NMIBC CIS has already gained traction, with the product now broadly available through both commercial and government insurance programs. The company recently announced that the Centers for Medicare & Medicaid Services in the United States has assigned a unique, permanent Healthcare Common Procedure Coding System J-code for Anktiva. This is expected to simplify the reimbursement process while increasing accessibility to patients. Currently, commercial and government insurance plans provide coverage for more than 240 million lives for Anktiva. In the past three months, ImmunityBio shares have lost 14.4% compared with the industry\u2019s 12.2% decline. Zacks Investment Research Image Source: Zacks Investment Research IBRX Provides Other Regulatory Updates on Pipeline Programs In a separate press release, ImmunityBio reported substantial progress in its ongoing discussions with the FDA concerning three therapeutic areas of its clinical development pipeline for NMIBC and non-small cell lung cancer (NSCLC). This has also likely fueled the stock price rise. The company announced that it is currently gearing up to submit a supplemental BLA in 2025 for Anktiva + BCG to treat BCG-unresponsive NMIBC in the papillary indication. Clinical data has shown a disease-free rate of 55% at 12 months, 51% at 18 months, and 48% at 24 months, upon treatment with the combo therapy. Additionally, 93% of patients avoided cystectomy (removal of bladder) after a median follow-up of 20.7 months. ImmunityBio believes that this immunotherapy, combining Anktiva with BCG, could provide an alternative for patients with BCG unresponsive NMIBC in papillary disease who have limited treatment options. Subject to approval, this immunotherapy could help patients avoid the high risks associated with radical total cystectomy while expanding the therapy's reach to a broader patient population. Story Continues IBRX is also planning to submit a BLA seeking approval for Anktiva as a monotherapy for second and third-line treatment of patients with NSCLC, who are progressing on checkpoint inhibitors. The regulatory filing will be supported by results from the mid-stage QUILT-3.055 study which demonstrated a median overall survival for all patients at 14.1 months upon treatment with the drug. In PD-L1 negative NSCL patients, the median overall survival extended to 15.8 months. ImmunityBio is simultaneously evaluating Anktiva, either as a monotherapy or in combination with other agents, for other cancer indications in separate clinical studies across various stages of development. ImmunityBio, Inc. Price and Consensus ImmunityBio, Inc. Price and Consensus ImmunityBio, Inc. price-consensus-chart | ImmunityBio, Inc. Quote IBRX\u2019s Zacks Rank and Stocks to Consider ImmunityBio currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and BioMarin Pharmaceutical BMRN, each sportinga Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 30 days, Castle Biosciences\u2019 earnings estimates for 2024 have remained constant at 34 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 23.2%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 30 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 28.2%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. In the past 30 days, estimates for BioMarin Pharmaceutical\u2019s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have increased from $3.94 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 12.6%. BMRN\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report ImmunityBio, Inc. (IBRX) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CTMX", "date": "2025-01-17T14:35:00+00:00", "sentiment": {"score": 0.9199162665754557, "confidence": 0.9474716782569885, "probabilities": {"positive": 0.9474716782569885, "negative": 0.02755541168153286, "neutral": 0.02497289888560772}}, "embedding": [-0.05914520472288132, -0.07979321479797363, -0.04019913077354431, -0.046359606087207794, -0.15423399209976196, 0.01034516654908657, -0.01839900203049183, 0.16747035086154938, 0.04203306511044502, -0.01110413670539856, -0.04280265420675278, 0.0018788495799526572, 0.125849187374115, 0.07105375081300735, -0.038500115275382996, 0.06068970263004303, 0.08710438758134842, -0.03844631463289261, -0.10802764445543289, 0.06130004674196243, -0.07795657962560654, 0.009915124624967575, 0.04213711619377136, 0.02180671878159046, -0.06636996567249298, -0.11242711544036865, -0.04696425050497055, -0.09190763533115387, -0.06944245100021362, -0.10630223155021667, 0.034111469984054565, 0.05013180151581764, 0.014948051422834396, -0.11511543393135071, -0.0023387507535517216, -0.056455761194229126, -0.0962420105934143, 0.04973912239074707, -0.10022349655628204, -0.047307614237070084, -0.019045522436499596, -0.0450456440448761, -0.14728610217571259, 0.09659232199192047, 0.11529618501663208, -0.024402756243944168, -0.10265961289405823, -0.00706401327624917, 0.018343806266784668, 0.12904292345046997, -0.1433892399072647, -0.09419533610343933, 0.06509719789028168, 0.13126309216022491, 0.0005450078751891851, -0.19422829151153564, -0.22639310359954834, -0.03493567556142807, 0.052580639719963074, -0.003077547997236252, -0.009440189227461815, -0.08218693733215332, 0.07668429613113403, 0.049631208181381226, 0.06934033334255219, 0.13192881643772125, 0.04466547071933746, -0.05579882860183716, -0.10030081868171692, -0.150079607963562, -0.005751081742346287, -0.16362297534942627, 0.0045679910108447075, 0.18484440445899963, -0.03726616129279137, 0.13863825798034668, 0.11884745955467224, 0.10820969939231873, 0.11526507139205933, -0.021842671558260918, 0.01869441568851471, 0.06800100952386856, 0.09551607072353363, 0.07785236835479736, 0.03135349601507187, 0.002420240081846714, 0.03439086303114891, 0.051067449152469635, 0.03937982767820358, 0.03309137374162674, 0.1755729615688324, 0.02597200497984886, 0.08141133189201355, -0.011933686211705208, -0.015839915722608566, -0.07155795395374298, -0.04216725006699562, 0.05756637826561928, 0.050642289221286774, -0.03686138242483139, 0.0023716003634035587, -0.03336331620812416, -0.09919673204421997, -0.011824858374893665, -0.10118424892425537, -0.07528413832187653, 0.043789319694042206, -0.07831642031669617, 0.23914435505867004, 0.02786172181367874, -0.054361868649721146, 0.023879824206233025, -0.0012753698974847794, -0.09644713252782822, -0.12283185869455338, 0.2248166799545288, -0.01348158624023199, 0.02452331967651844, 0.317440390586853, -0.06831969320774078, 0.0307660773396492, -0.011542083695530891, -0.00707752350717783, -0.05291933938860893, 0.14630010724067688, 0.08099047094583511, -0.09520258009433746, 1.192978800733212e-32, -0.1283450424671173, -0.02995223179459572, 0.09600627422332764, 0.09025515615940094, -0.11289002746343613, -0.08465708792209625, 0.061547257006168365, -0.08599604666233063, -0.14413535594940186, -0.1703639030456543, -0.1583067625761032, 0.01658986695110798, -0.04931382089853287, 0.07332153618335724, -0.0654304102063179, -0.04453336074948311, -0.058686379343271255, -0.051783621311187744, -0.11378394812345505, 0.09560735523700714, 0.12548226118087769, 0.04811657592654228, 0.053328316658735275, 0.03864581137895584, 0.0571119599044323, 0.0984983742237091, 0.011019358411431313, 0.010238522663712502, 0.020239651203155518, 0.03452024608850479, -0.08385781943798065, 0.08475957065820694, -0.01812116429209709, -0.03222110494971275, -0.061060696840286255, -0.06245867908000946, 0.02328992635011673, -0.019624032080173492, -0.026914160698652267, 0.05380184203386307, -0.01882166974246502, 0.054164331406354904, -0.09324511140584946, -0.09535427391529083, 0.17203934490680695, -0.09040975570678711, -0.136489599943161, -0.057001642882823944, 0.020955264568328857, -0.04467111825942993, 0.01688287779688835, 0.046749264001846313, -0.05832970514893532, -0.050469543784856796, 0.052060045301914215, 0.028778674080967903, -0.14418193697929382, 0.02256879024207592, 0.06008321791887283, 0.15532052516937256, 0.005714463070034981, 0.02734394185245037, -0.06450378894805908, 0.018401166424155235, -0.08992728590965271, 0.11307376623153687, -0.023928429931402206, -0.048373665660619736, -0.14857196807861328, 0.02120322734117508, -0.033845048397779465, 0.0997886136174202, 0.14299586415290833, -0.007927833124995232, 0.005899147596210241, -0.13067340850830078, 0.01842029206454754, 0.06012319028377533, 0.018442749977111816, -0.005887053906917572, 0.02827056497335434, -0.01402188092470169, -0.04710327088832855, 0.20380732417106628, 0.057596929371356964, -0.11256059259176254, 0.006183678284287453, 0.07916080951690674, -0.10614002496004105, -0.06023930758237839, 0.12353597581386566, 0.03336964547634125, -0.07370136678218842, 0.15606212615966797, 0.04354606568813324, -1.092215939259504e-32, 0.014660758897662163, -0.010742884129285812, 0.04164645075798035, -0.035325467586517334, -0.029527053236961365, 0.0824878066778183, 0.1870109587907791, -0.07246653735637665, 0.1202060878276825, -0.04895897954702377, 0.04309932887554169, 0.10990391671657562, 0.018211673945188522, 0.03162673860788345, -0.10676112025976181, 0.08306553959846497, 0.034606967121362686, -0.03199028596282005, -0.16679513454437256, 0.05610103905200958, 0.06038477644324303, 0.11731558293104172, -0.03557850047945976, 0.001989792101085186, -0.07947425544261932, 0.15187907218933105, 0.07218518108129501, 0.20270700752735138, 0.1320105791091919, -0.14200511574745178, -0.12325647473335266, 0.09491828083992004, -0.19798308610916138, -0.09073424339294434, -0.05013124644756317, -0.08613132685422897, 0.02361331135034561, -0.10481971502304077, -0.05259065330028534, -0.11509290337562561, -0.011666495352983475, 0.008304484188556671, -0.1531156599521637, 0.016142111271619797, 0.09791170060634613, 0.09067391604185104, 0.12952080368995667, -0.06474277377128601, 0.18547119200229645, -0.035736292600631714, 0.07033335417509079, -0.019530944526195526, 0.027030834928154945, 0.08962942659854889, -0.07084259390830994, -0.11146672815084457, 0.023836523294448853, -0.1186656653881073, -0.04177046939730644, 0.042060378938913345, 0.024794524535536766, 0.10906475782394409, 0.14849138259887695, -0.12356069684028625, 0.02233029529452324, 0.16713640093803406, 0.04539012163877487, -0.04322032257914543, 0.05738648772239685, -0.0961616262793541, -0.056203052401542664, -0.07869203388690948, -0.04089145362377167, -0.15757045149803162, 0.03857908397912979, 0.11833236366510391, 0.05318629741668701, -0.12829504907131195, -0.03662232682108879, 0.01959536224603653, -0.0800299271941185, 0.007357340771704912, 0.05043163150548935, 0.01839091069996357, 0.17230767011642456, 0.1509905755519867, 0.014300658367574215, -0.11776842176914215, 0.04197658970952034, 0.061869971454143524, -0.139093816280365, -0.004585737362504005, 0.0019222721457481384, 0.07228407263755798, -0.00323818763718009, -1.0070911571347096e-07, 0.09161113202571869, -0.0735088661313057, -0.09281692653894424, -0.10208937525749207, 0.04554656147956848, -0.04881761223077774, -0.11628212034702301, -0.013144008815288544, 0.006084562279284, 0.0882742777466774, 0.0974523052573204, 0.15108808875083923, -0.10540521144866943, -0.0189792662858963, -0.006309313699603081, -0.012379206717014313, -0.062430690973997116, 0.03258266672492027, -0.01854013465344906, -0.024081731215119362, -0.131999671459198, -0.05054869130253792, 0.043014418333768845, -0.02950284071266651, 0.03148332238197327, -0.08434823900461197, -0.019830267876386642, 0.04643726348876953, 0.11042304337024689, -0.07692806422710419, -0.06789816170930862, -0.06867331266403198, 0.05599519610404968, 0.0412522628903389, -0.1034141331911087, -0.15250182151794434, 0.034704554826021194, 0.09531435370445251, 0.12661537528038025, 0.0794769898056984, 0.0785951018333435, -0.08461789786815643, -0.0024940241128206253, -0.003404727205634117, -0.033596668392419815, -0.03076307475566864, -0.20801518857479095, -0.129299134016037, 0.02879529818892479, -0.0311814583837986, 0.03509078174829483, -0.10762204229831696, -0.0019436618313193321, -0.0007325061596930027, -0.041309889405965805, 0.08931641280651093, -0.01976761408150196, -0.11396025121212006, 0.05153186619281769, 0.00996940117329359, 0.04022446274757385, -0.24818915128707886, 0.049378737807273865, 0.06695916503667831], "changes": {"1wk": 6.071428647454907}}, {"text": "ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate Zacks Equity Research Fri, Jan 17, 2025, 5:24 PM 5 min read In This Article: ATRA -4.05% Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after the FDA issued a complete response letter (CRL)\u00a0against the company\u2019s biologics license application (BLA) seeking approval of lead product candidate, tabelecleucel (tab-cel), for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in adult and pediatric patients aged two years and older. The intended patient population includes EBV+ PTLD patients, who have received at least one prior therapy, including an anti-CD20-containing regimen. Tab-cel, the company\u2019s novel T-cell immunotherapy, is already marketed in the EU under the brand name, Ebvallo, by Atara\u2019s partner Pierre Fabre under an exclusive commercialization and license agreement. EBV+ PTLD is a rare hematologic malignancy (blood cancer) with a high mortality rate and occurs after patients undergo transplantation when their T-cell immune responses are compromised by immunosuppression. In the past three months, Atara shares have lost 16.8% compared with the industry\u2019s 12.2% decline. Zacks Investment Research Image Source: Zacks Investment Research More on the FDA\u2019s CRL Issuance Against ATRA\u2019s Ebvallo Atara clarified that the FDA\u2019s CRL was exclusively linked to observations from a routine pre-license inspection of a third-party manufacturing facility for Ebvallo. It did not highlight any issues with the manufacturing process, clinical efficacy, or clinical safety data included in the BLA. Moreover, the FDA did not ask for additional clinical studies to support Ebvallo\u2019s approval. Atara\u2019s BLA submission in the United States seeking approval for Ebvallo to treat EBV+ PTLD was based on the pivotal phase III ALLELE study results. Per the data readout, a statistically significant 50% objective response rate was achieved upon treatment of EBV+ PTLD patients with the drug. As the next steps in the regulatory process, Atara announced that it is working closely with its partner Pierre Fabre Laboratories, the FDA and the concerned third-party manufacturer to resolve the issues stated in the CRL to support Ebvallo\u2019s approval for EBV+ PTLD. Subsequently, the company will be resubmitting the Ebvallo BLA to the FDA which it expects to be potentially approved within six months of resubmission. The CRL for Ebvallo BLA has postponed the drug's U.S. market entry. This delay represents lost revenue potential, as the company could have begun capitalizing on market opportunities sooner in the absence of the CRL. Atara is eligible to receive a $60 million milestone payment from Pierre Fabre upon FDA approval of the Ebvallo BLA, providing a critical cash infusion for the company. Additionally, it will be eligible for substantial double-digit tiered royalties based on net sales and further milestones tied to Ebvallo's commercial performance. However, the FDA's CRL has also delayed the milestone payment, impacting funds the company planned to allocate for supporting operational activities. Story Continues ATRA Seeking Strategic Alternatives Amid Severe Cash Crunch The company\u2019s pipeline also comprises several next-generation allogeneic CAR T programs, which are predominantly in the pre-clinical stage. One CAR T-cell therapy, ATA3219, is undergoing early-stage development for non-Hodgkin\u2019s lymphoma. Atara deems its current cash position to be insufficient to support these pipeline programs without additional funding. This could have also contributed to the stock price decline. The company reported preliminary cash, cash equivalents and short-term investments of approximately $43 million as of Dec. 31, 2024. If a strategic funding solution for its CAR-T development programs is not secured in first-quarter 2025, Atara plans to halt all CAR-T activities and significantly scale back its operations. The company would focus solely on supporting Ebvallo\u2019s approval, including progressively transferring all related operational activities to Pierre Fabre in the near term. Atara has signed a non-binding term sheet with Redmile Group for up to $15 million in equity funding, deemed sufficient for Ebvallo BLA approval efforts, while also exploring alternative, including non-dilutive, financing options. In the long term, Atara stated that it is looking into strategic alternatives, including acquisition, merger, reverse merger, other business combinations, sale of assets, or other strategic transactions to advance the development of its CAR-T assets. Although the company did not guarantee a deal, it is currently in talks with several potential parties. Atara Biotherapeutics, Inc. Price and Consensus Atara Biotherapeutics, Inc. Price and Consensus Atara Biotherapeutics, Inc. price-consensus-chart | Atara Biotherapeutics, Inc. Quote ATRA\u2019s Zacks Rank & Stocks to Consider Atara currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and BioMarin Pharmaceutical BMRN, each sportinga Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 30 days, Castle Biosciences\u2019 earnings estimates for 2024 have remained constant at 34 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 23.2%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 30 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have lost 28.2%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. In the past 30 days, estimates for BioMarin Pharmaceutical\u2019s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have increased from $3.94 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 12.6%. BMRN\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Atara Biotherapeutics, Inc. (ATRA) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CTMX", "date": "2025-01-17T14:24:00+00:00", "sentiment": {"score": -0.5930025726556778, "confidence": 0.7218412160873413, "probabilities": {"positive": 0.1288386434316635, "negative": 0.7218412160873413, "neutral": 0.14932017028331757}}, "embedding": [-0.15347212553024292, -0.0019126925617456436, -0.10983042418956757, -0.1418880820274353, -0.06304633617401123, 0.03533667325973511, 0.024831034243106842, 0.22040587663650513, 0.14308062195777893, 0.07901120185852051, -0.0807085707783699, 0.03577986732125282, 0.0827179104089737, -0.022065075114369392, -0.03836292773485184, -0.00565000856295228, 0.10684770345687866, -0.10069513320922852, -0.1331610083580017, -0.011314012110233307, -0.06895115226507187, -0.02954857423901558, 0.06513924151659012, 0.10565372556447983, -0.10105212032794952, -0.08077982068061829, -0.16461116075515747, 0.0022950172424316406, -0.15868346393108368, -0.11217615008354187, 0.028030885383486748, 0.07922613620758057, -0.0016569634899497032, -0.10542695969343185, -0.03437900170683861, -0.0688275694847107, -0.14309187233448029, 0.08365355432033539, -0.1890202760696411, -0.0999133437871933, 0.037976156920194626, -0.13266611099243164, -0.17934474349021912, 0.01581074856221676, 0.03853374719619751, -0.12159515172243118, -0.028953388333320618, -0.0909944474697113, 0.0670224130153656, 0.16288244724273682, -0.0546891912817955, 0.011238481849431992, -0.047248683869838715, 0.026593323796987534, -0.09724946320056915, -0.0537080354988575, -0.10875488817691803, -0.04095514863729477, 0.05822036415338516, -0.0336192287504673, -0.013340923935174942, -0.08914335072040558, 0.013082584366202354, 0.05247887969017029, 0.009176625870168209, 0.009464289993047714, 0.03507238253951073, -0.0985202044248581, -0.07966388761997223, -0.04219662398099899, 0.08521245419979095, -0.09470659494400024, -0.05258740484714508, 0.25891274213790894, -0.02749793790280819, 0.06119229644536972, 0.1860145926475525, 0.1536933332681656, 0.10624842345714569, -0.045428864657878876, -0.09109707921743393, 0.05711738020181656, -0.026023656129837036, 0.038321562111377716, -0.021069131791591644, 0.09288937598466873, -0.06013929098844528, 0.1134076863527298, 0.08851999044418335, 0.015238986350595951, 0.21839798986911774, 0.044156093150377274, 0.08948691934347153, 0.03659839928150177, 0.08820405602455139, 0.025174975395202637, -0.009604322724044323, -0.03983231633901596, 0.032554809004068375, -0.04948427528142929, -0.0366193912923336, 0.007058833725750446, -0.10862748324871063, -0.01433187909424305, -0.07530352473258972, -0.1364540159702301, 0.007264356128871441, -0.049711357802152634, 0.05184595286846161, -0.05066616088151932, -0.018284305930137634, -0.04812799021601677, 0.019230714067816734, -0.037641920149326324, -0.04898000881075859, 0.18589723110198975, -0.08348160982131958, -0.046390458941459656, 0.27506694197654724, -0.09340269863605499, 0.03950870782136917, -0.012568319216370583, 0.027461133897304535, 0.013366756029427052, 0.0937054380774498, 0.024622280150651932, -0.017131583765149117, 1.3481876952695283e-32, -0.021820195019245148, 0.026290273293852806, -0.009052710607647896, 0.07610779255628586, -0.037644460797309875, 0.05510861799120903, 0.15350092947483063, 0.04362563416361809, -0.15072180330753326, -0.0949491411447525, -0.16734693944454193, -0.0059275454841554165, 0.10505881905555725, 0.09761595726013184, -0.22785741090774536, -0.050008852034807205, -0.06554009765386581, -0.03816474601626396, -0.16800716519355774, 0.010555693879723549, 0.014889076352119446, 0.05724019557237625, 0.047817058861255646, 0.07002010941505432, -0.08769991248846054, 0.034144528210163116, -0.13038116693496704, 0.09078817814588547, 0.028020672500133514, 0.09717538952827454, -0.07438734173774719, 0.00924388412386179, 0.1155044436454773, -0.09214180707931519, -0.05595453083515167, -0.009861588478088379, -0.07784080505371094, 0.08847096562385559, 0.0634186863899231, 0.12446717917919159, 0.12241759896278381, 0.06291092932224274, -0.16990673542022705, 0.05205202102661133, 0.07931119948625565, -0.1096661388874054, -0.08827947080135345, -0.07369864732027054, -0.1462903767824173, -0.004060895647853613, 0.019434181973338127, 0.0006855376996099949, -0.015305604785680771, -0.009842149913311005, -0.11201073229312897, 0.08089239150285721, -0.10395920276641846, 0.05681552737951279, 0.0986609160900116, 0.04484029486775398, 0.03001617081463337, 0.20208923518657684, -0.004835929721593857, 0.06822692602872849, -0.09081833064556122, 0.0729307234287262, 0.10738255083560944, -0.1238236129283905, -0.17159050703048706, 0.02703220024704933, 0.09687736630439758, 0.014683781191706657, 0.12198014557361603, 0.041340433061122894, 0.09964853525161743, -0.07877510786056519, 0.015776880085468292, 0.16061986982822418, 0.03298765420913696, 0.044463396072387695, -0.0391487292945385, 0.002114427275955677, -0.04065416380763054, 0.14539256691932678, 0.044958434998989105, -0.11855822801589966, -0.055387742817401886, -0.027413178235292435, -0.14636558294296265, -0.00751532381400466, 0.15545865893363953, -0.007916045375168324, -0.04494393616914749, 0.12234801799058914, 0.08149820566177368, -1.2259581028978975e-32, 0.01172984391450882, -0.009652413427829742, 0.06465639173984528, -0.023139525204896927, 0.027330737560987473, 0.056629423052072525, 0.15013326704502106, -0.0871591567993164, 0.19127584993839264, -0.024375837296247482, 0.16150473058223724, 0.03771691024303436, -0.0902862697839737, -0.004115393850952387, -0.04604344815015793, 0.06327930092811584, -0.01650247722864151, -0.03374689072370529, -0.14208373427391052, 0.07262711971998215, 0.01863046921789646, 0.06173311918973923, -0.03074903041124344, 0.11517655849456787, 0.02279583178460598, 0.04721284657716751, 0.01738116517663002, 0.05331612005829811, 0.08101862668991089, -0.12911416590213776, -0.07884179055690765, 0.000587165355682373, -0.16814157366752625, 0.05056407302618027, -0.077547587454319, -0.061235133558511734, -0.0021024178713560104, -0.09408101439476013, 0.04703325033187866, -0.14578109979629517, 0.09237529337406158, 0.022170357406139374, -0.06221582368016243, -0.04973110556602478, 0.04770287498831749, 0.1049063578248024, 0.05195891484618187, 0.04860777407884598, 0.1934921145439148, 0.06754419207572937, 0.007118465378880501, 0.027797918766736984, 0.13934966921806335, 0.058019861578941345, -0.015438172966241837, -0.015458699315786362, 0.08232276141643524, -0.0128251351416111, -0.13555067777633667, 0.058760590851306915, 0.04695647209882736, 0.07004532217979431, 0.1009397804737091, -0.0032795649021863937, 0.12054552137851715, 0.18036431074142456, 0.08987334370613098, -0.035501718521118164, 0.013321062549948692, -0.14327849447727203, 0.009533368982374668, -0.13274508714675903, -0.07653568685054779, -0.23332399129867554, 0.010453542694449425, 0.08226092904806137, -0.05349186062812805, -0.06235634535551071, -0.07247363030910492, -0.04639125615358353, -0.05264381319284439, -0.041064199060201645, 0.02779374085366726, -0.036634184420108795, 0.04049171879887581, 0.1178911030292511, -0.10172875970602036, -0.09767764061689377, 0.024362387135624886, 0.11470356583595276, -0.0632288008928299, -0.08385099470615387, -0.04879927262663841, 0.07486552000045776, 0.0629761666059494, -1.0006472450641013e-07, 0.12343612313270569, -0.05978592857718468, -0.020749147981405258, -0.05652805417776108, 0.0922824889421463, -0.06466300040483475, -0.03818497061729431, 0.06383313238620758, 0.06113781780004501, 0.0850929468870163, -0.04553345590829849, 0.10716141760349274, -0.13083963096141815, -0.019324898719787598, -0.06429608166217804, 0.08528578281402588, -0.03245199844241142, -0.02414817549288273, -0.0035247374325990677, -0.02708934061229229, -0.025379450991749763, 0.002878260798752308, 0.1408807635307312, -0.08410923182964325, 0.021159393712878227, -0.016267523169517517, 0.01649829000234604, -0.01564486138522625, 0.10129573941230774, -0.22810235619544983, -0.049396198242902756, -0.09034562110900879, 0.007679492700845003, 0.10049080848693848, -0.024286866188049316, -0.10910754650831223, 0.11073029786348343, 0.01763090118765831, 0.03575305640697479, 0.11701840162277222, 0.029414590448141098, 0.09280765056610107, -0.009019291028380394, -0.06778046488761902, -0.012948967516422272, 0.028851250186562538, -0.16984790563583374, -0.06318888813257217, -0.07314871996641159, -0.21205246448516846, -0.037445440888404846, 0.031140536069869995, 0.003506658598780632, -0.0313514769077301, -0.15781831741333008, 0.11312471330165863, -0.08200021088123322, -0.052762728184461594, 0.12485308945178986, -0.0030756008345633745, 0.0693703144788742, -0.11484169960021973, 0.09385798871517181, 0.07342375814914703], "changes": {"1wk": 3.3333330968069577}}, {"text": "MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results Zacks Equity Research Thu, Jan 16, 2025, 8:09 PM 4 min read In This Article: MIRM -0.59% Shares of Mirum Pharmaceuticals MIRM were up 12.1% this week, driven by investor enthusiasm after the company announced encouraging preliminary sales numbers for the fourth quarter and full year 2024, along with an encouraging outlook and growth strategy for 2025. Mirum\u2019s commercial portfolio comprises of lead product, Livmarli (maralixibat), which is approved for treating cholestatic pruritus in patients with Alagille syndrome worldwide. The drug is also approved for treating certain patients with progressive familial intrahepatic cholestasis in the United States and Europe. MIRM acquired Travere Therapeutics\u2019 bile acid products in August 2023, which added the latter\u2019s Cholbam capsules and Chenodal tablets to its portfolio of commercialized drugs. In the past year, shares of Mirum have rallied 73.3% against the industry\u2019s decline of 16%. Zacks Investment Research Image Source: Zacks Investment Research MIRM's Preliminary Results for 2024 The company reported preliminary net product sales of approximately $336 million in 2024, which surpassed the upper end of the guided range of $330-$335 million, provided with the third-quarter 2024 earnings release in November. The company expects preliminary net product sales of Livmarli to be around $64 million in the fourth quarter and $213 million for full-year 2024. Preliminary net product sales from Cholbam and Chenodal are expected to be around $35 million in the fourth quarter and $123 million for full-year 2024. Cholbam is approved for treating bile acid synthesis disorders and Zellweger spectrum disorders. Mirum\u2019s cash, cash equivalents and investments were around $287 million as of Dec. 31, 2024. The company achieved positive cash flow from operations in the third quarter of 2024. MIRM's 2025 Guidance & Business Goals The company anticipates net product sales of around $420-$435 million for full-year 2025. Mirum is evaluating Livmarli in the phase III EXPAND study for treating pruritus in rare cholestatic conditions. Enrollment in the study is expected to be completed in 2026. Meanwhile, a new drug application seeking approval for Chenodiol for cerebrotendinous xanthomatosis (\u201cCTX\u201d) patients is currently under review in the United States. A decision from the FDA is now expected on March 28, 2025. Chenodiol is not currently approved but has received a medical necessity medicine status from the FDA for treating CTX. Mirum\u2019s lead pipeline candidate, volixibat, is currently being evaluated in two phase IIb studies for treating patients with primary biliary cholangitis (the VANTAGE study) and primary sclerosing cholangitis (the VISTAS study). Story Continues Enrollment in the VISTAS study is expected to be completed in the second half of 2025 and top-line data from the same is anticipated in 2026. The company expects to complete enrollment in the VANTAGE study in 2026. MIRM also plans to initiate a phase II study on its recently in-licensed PDE4D inhibitor, MRM-3379, for treating Fragile X syndrome later in 2025. Mirum Pharmaceuticals, Inc. Price Mirum Pharmaceuticals, Inc. Price Mirum Pharmaceuticals, Inc. price | Mirum Pharmaceuticals, Inc. Quote MIRM's Zacks Rank & Other Stocks to Consider Mirum currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the biotech sector are Voyager Therapeutics, Inc. VYGR, CytomX Therapeutics, Inc. CTMX and Castle Biosciences, Inc. CSTL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 60 days, estimates for Voyager Therapeutics\u2019 loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 29%. VYGR\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 120.87%. In the past 60 days, estimates for CytomX Therapeutics\u2019 loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have increased 16.6%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%. In the past 60 days, estimates for Castle Biosciences\u2019 loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged 29.9%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Voyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Mirum Pharmaceuticals, Inc. (MIRM) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CTMX", "date": "2025-01-16T17:09:00+00:00", "sentiment": {"score": 0.908129028044641, "confidence": 0.9192629456520081, "probabilities": {"positive": 0.9192629456520081, "negative": 0.011133917607367039, "neutral": 0.06960316002368927}}, "embedding": [0.04953783378005028, -0.2447274923324585, -0.11426202952861786, 0.00797922071069479, -0.15935489535331726, 0.03677805885672569, -0.039571743458509445, 0.30680328607559204, 0.11646950244903564, 0.08124396204948425, 0.019984353333711624, 0.08184943348169327, 0.009674419648945332, 0.0420144684612751, -0.016791416332125664, 0.09310571849346161, 0.041718997061252594, -0.05784980580210686, -0.11702887713909149, 0.04039362072944641, -0.04204897582530975, -0.1267251968383789, 0.059804532676935196, -0.04542943835258484, -0.06383341550827026, 0.07478778064250946, -0.018021652474999428, -0.0664849504828453, -0.0849621370434761, -0.04772515967488289, 0.07628975063562393, 0.1436854600906372, 0.17540153861045837, -0.17641109228134155, -0.04648584872484207, 0.014427357353270054, -0.1219053715467453, 0.04769454896450043, 0.011196828447282314, -0.0084701431915164, -0.0287821926176548, -0.07251878082752228, -0.15304860472679138, -0.07913864403963089, -0.07367637753486633, -0.19988250732421875, 0.03488101065158844, 0.06487482786178589, 0.033552106469869614, 0.2306244969367981, -0.2934124767780304, -0.08275049924850464, 0.04372018575668335, 0.07509419322013855, -0.1111849844455719, -0.007133114151656628, -0.07890580594539642, -0.0981445237994194, -0.007902724668383598, -0.019677599892020226, -0.05836973339319229, -0.10499724745750427, 0.017384320497512817, -0.10316143184900284, -0.027326323091983795, 0.019720394164323807, 0.0077388230711221695, -0.0837826281785965, 0.09742795675992966, -0.03866483271121979, 0.15817609429359436, -0.05408812314271927, -0.08583612740039825, 0.10127370059490204, -0.07514511048793793, 0.1576896756887436, 0.15925903618335724, 0.015109511092305183, 0.11651264131069183, -0.11819131672382355, 0.021044045686721802, 0.04270344227552414, 0.033086761832237244, -0.04430021345615387, 0.03377668187022209, 0.17362293601036072, 0.014889962039887905, 0.16629359126091003, 0.08829865604639053, 0.010371789336204529, 0.12511426210403442, 0.05240051820874214, -0.06271440535783768, -0.020895639434456825, -0.08555218577384949, -0.03183220326900482, -0.044742655009031296, 0.01797303929924965, -0.03914441540837288, 0.011608005501329899, 0.10094492137432098, 0.03883654624223709, -0.10544727742671967, -0.283610999584198, -0.0006567677482962608, -0.16218161582946777, 0.06563062220811844, -0.027893515303730965, 0.04600929468870163, 0.002362133702263236, -0.07814780622720718, -0.029975444078445435, -0.026609905064105988, -0.0298724714666605, -0.09796759486198425, 0.23500728607177734, 0.006854515057057142, -0.006723551545292139, 0.17149636149406433, 0.11138954758644104, 0.08431737124919891, 0.07087139785289764, 0.006897643208503723, -0.08941478282213211, -0.02788316272199154, -0.14430460333824158, -0.15541502833366394, 1.4523816043480958e-32, -0.06384450197219849, 0.035767581313848495, 0.011609187349677086, 0.04879526421427727, -0.06405645608901978, -0.044968098402023315, 0.10589553415775299, -0.0009633294539526105, 0.004067927598953247, -0.24495548009872437, -0.1484341025352478, 0.05218295007944107, -0.116189144551754, 0.06852161884307861, -0.05618558079004288, -0.030384503304958344, -0.011073734611272812, 0.009635623544454575, 0.043629709631204605, -0.029301179572939873, -0.02371010184288025, -0.00666474923491478, -0.07529043406248093, 0.073645681142807, -0.053631529211997986, 0.1445951759815216, 0.07079450786113739, 0.04613855853676796, 0.11572709679603577, 0.0787212923169136, -0.03494727239012718, 0.03183508664369583, 0.01140549499541521, -0.15749526023864746, -0.10462382435798645, 0.060454756021499634, -0.1544349640607834, -0.03413959965109825, -0.01702403649687767, 0.15903162956237793, -0.0317273885011673, 0.07734186947345734, -0.09805275499820709, 0.03274250403046608, -0.0021235663443803787, -0.04970638453960419, -0.11437588930130005, 0.010868784040212631, 0.025993114337325096, -0.09853252023458481, 0.007465572562068701, 0.08943529427051544, 0.014980809763073921, 0.08526611328125, -0.02448241412639618, -0.14234231412410736, -0.13976424932479858, -0.07924866676330566, 0.01405363343656063, 0.08070319890975952, 0.017330287024378777, 0.047361116856336594, 0.005411584861576557, 0.1498325616121292, -0.14856065809726715, 0.09522649645805359, -0.07513181120157242, -0.11390533298254013, -0.12708505988121033, 0.1361655443906784, 0.03518504649400711, 0.010754955001175404, 0.0569886788725853, -0.05092732608318329, 0.01395995169878006, -0.17339234054088593, 0.08869333565235138, 0.07987258583307266, 0.04031629487872124, 0.08446456491947174, 0.053273096680641174, 0.03755806386470795, -0.016781313344836235, 0.10453109443187714, -0.07249085605144501, 0.0381164625287056, 0.0022876793518662453, 0.0373314693570137, -0.11893947422504425, -0.05729404836893082, 0.08352887630462646, 0.020318230614066124, -0.11751444637775421, 0.1756170392036438, -0.018879737704992294, -1.2720989744983586e-32, -0.14312732219696045, 0.059437207877635956, -0.003262404352426529, 0.03309958800673485, -0.08730027079582214, 0.15518715977668762, 0.019498400390148163, -0.005990423262119293, 0.09435202181339264, -0.009124286472797394, -0.009074274450540543, 0.01684112474322319, -0.00042777368798851967, 0.07858514785766602, -0.1547265201807022, 0.06519874185323715, 0.20884674787521362, -0.09835854172706604, 0.04322317987680435, -0.036680929362773895, -0.040925282984972, 0.28366467356681824, -0.07861829549074173, 0.11494462192058563, 0.001958949491381645, 0.08673574775457382, 0.05403969809412956, 0.0010164491832256317, -0.047262921929359436, 0.04701564460992813, 0.06171495467424393, -0.07722783833742142, -0.20730939507484436, 0.0539330393075943, -0.09329633414745331, -0.011420298367738724, 0.053644392639398575, -0.19737163186073303, -0.0387454628944397, -0.017247579991817474, 0.07399709522724152, -0.0980338305234909, 0.06088327616453171, 0.057076480239629745, -0.015662258490920067, -0.09225144982337952, 0.09170569479465485, -0.04843449592590332, 0.17328722774982452, 0.09618070721626282, -0.005038285627961159, 0.05626734346151352, -0.0638037919998169, 0.0004561943933367729, -0.05134480819106102, -0.013123709708452225, -0.004979560151696205, -0.019745487719774246, -0.06877531111240387, -0.07368060946464539, -0.15081462264060974, 0.12142917513847351, 0.04684631526470184, -0.042463354766368866, 0.01940244436264038, 0.25110575556755066, 0.1992616206407547, -0.008825156837701797, 0.03163839504122734, -0.23032352328300476, 0.026510361582040787, 0.024037454277276993, 0.001738312654197216, -0.02773500606417656, 0.036396533250808716, 0.23899246752262115, 0.04187767580151558, -0.04219727963209152, -0.05903247743844986, -0.12624023854732513, -0.06339802592992783, -0.1534600555896759, 0.05632326006889343, 0.007573295384645462, 0.004630104638636112, 0.017778513953089714, -0.01801617071032524, -0.04054897278547287, -0.13751254975795746, 0.03467980772256851, -0.008151687681674957, -0.0988207459449768, -0.09306143969297409, 0.02207910642027855, 0.18967604637145996, -1.0093525304455397e-07, 0.09258151799440384, -0.14368318021297455, -0.09989714622497559, 0.05098666250705719, 0.018980490043759346, -0.07345063984394073, -0.05645139142870903, 0.06554365158081055, 0.01730579324066639, 0.1530049741268158, 0.011280754581093788, 0.20814111828804016, -0.22448638081550598, 0.08317830413579941, -0.10458038747310638, 0.03438960015773773, -0.04096703976392746, 0.06700053066015244, -0.03969893977046013, -0.09396365284919739, -0.12525096535682678, 0.0421428382396698, 0.11753899604082108, -0.12356790155172348, 0.009021719917654991, 0.00041171349585056305, 0.02837534435093403, 0.010696993209421635, -0.019695717841386795, -0.009888190776109695, 0.12021911144256592, -0.062944695353508, 0.03919267654418945, 0.0833125188946724, 0.033772118389606476, -0.16752970218658447, 0.01654229313135147, 0.1461188793182373, 0.007449127733707428, 0.19954219460487366, 0.02563147060573101, -0.058680128306150436, -0.04458210617303848, 0.06886447966098785, -0.05235743895173073, -0.039148785173892975, -0.19552752375602722, -0.11434396356344223, 0.08521012961864471, -0.07394710183143616, 0.0009769389871507883, 0.07363404333591461, 0.16392941772937775, -0.047991592437028885, -0.07539073377847672, 0.19614145159721375, 0.04171350225806236, -0.10030525922775269, -0.12807977199554443, 0.06163971498608589, 0.09015330672264099, -0.21760521829128265, 0.045596398413181305, 0.1483030915260315], "changes": {"1wk": 2.4793350626890267}}, {"text": "InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug Zacks Equity Research Thu, Jan 16, 2025, 6:49 PM 4 min read In This Article: IFRX 0.00% InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing authorization, under exceptional circumstances, for Gohibic (vilobelimab) to treat adult patients with acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2. The targeted patient population in the EU comprises individuals receiving systemic corticosteroids as standard-of-care therapy and undergoing invasive mechanical ventilation, with or without extracorporeal membrane oxygenation. The EC\u2019s approval makes Gohibic the first and only approved treatment for SARS-CoV-2-induced ARDS in the EU. We remind the investors that in November 2024, the advisory committee to the European Medicines Agency had adopted a positive opinion recommending approval of the drug for the above indication, under exceptional circumstances. Gohibic is a first-in-class anti-C5a monoclonal antibody. More on the EC Nod for IFRX\u2019s COVID-19-Induced ARDS Drug The EU approval ofInflaRx\u2019s Gohibic for the ADRS indication is based on the previously announced results of the phase III PANAMO study, which evaluated the drug\u2019s efficacy in invasively mechanically ventilated COVID-19 patients in intensive care units. Per the data readout, vilobelimab treatment improved survival, reducing 28-day all-cause mortality by 23.9% compared to placebo in the global data set. InflaRx shares have surged 62.6% in the past three months against the industry\u2019s 13.5% decline. Zacks Investment Research Image Source: Zacks Investment Research Please note that marketing authorization under exceptional circumstances is granted when the benefit-risk assessment is positive, but the rarity of the disease makes it challenging to gather comprehensive data under normal conditions. Per the terms of Gohibic\u2019s approval in the EU, InflaRx will submit annual updates to the regulatory body in the EU on the planned clinical platform study by the Biomedical Advanced Research and Development Authority. The impending study includes vilobelimab as one of three potential new therapies for treating ARDS. The exceptional marketing authorization for c applies across all 27 EU member states, including Iceland, Liechtenstein and Norway. InflaRx is exploring commercial partnerships and distribution options in the EU, with minimal anticipated impact on its cash burn rate. Approval Status of IFRX\u2019s Gohibic in the US for COVID-19 In the United States, InflaRx\u2019s Gohibic has received Emergency Use Authorization from the FDA for treating critical adult COVID-19 patients, who have been hospitalized. This authorization remains valid only for the duration of the public health emergency declaration unless the declaration is ended or the authorization is revoked earlier. Leer m\u00e1s Please note that Gohibic is an investigational drug that has not received FDA approval for any indication, including the treatment of COVID-19. The safety and effectiveness of Gohibic for hospitalized COVID-19 patients remain limited. IFRX\u2019s Other Clinical Pipeline Programs Apart from the COVID-19 indication, InflaRx is also currently evaluating vilobelimab for pyoderma gangrenosum (PG) in a phase III study. Interim analysis results from the study are expected in the second quarter of 2025. Vilobelimab enjoys the orphan drug designation for the PG indication in the EU as well as the United States. Additionally, the candidate enjoys the FDA\u2019s Fast Track designation for the same indication. The company is also evaluating another candidate, INF904, an oral C5aR inhibitor, for patients with moderate-to-severe chronic spontaneous urticaria and moderate-to-severe hidradenitis suppurativa in a phase IIa basket study. Initial data is anticipated in the summer of 2025. InflaRx N.V. Price and Consensus InflaRx N.V. Price and Consensus InflaRx N.V. price-consensus-chart | InflaRx N.V. Quote IFRX\u2019s Zacks Rank & Stocks to Consider InflaRx currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the sector are Castle Biosciences CSTL, CytomX Therapeutics CTMX and BioMarin Pharmaceutical BMRN, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 30 days, Castle Biosciences\u2019 earnings estimates for 2024 have remained constant at 34 cents per share. During the same timeframe, loss per share for 2025 has remained constant at $1.84. In the past three months, shares of Castle Biosciences have plunged 24.4%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%. In the past 30 days, estimates for CytomX Therapeutics\u2019 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In the past three months, shares of CytomX Therapeutics have surged 63.8%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%. In the past 30 days, estimates for BioMarin Pharmaceutical\u2019s 2024 earnings per share have Improved from $3.28 to $3.29. Estimates for 2025 earnings per share have increased from $3.94 to $4.02 during the same timeframe. In the past three months, BioMarin Pharmaceutical shares have lost 11.4%. BMRN\u2019s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 28.7%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report InflaRx N.V. (IFRX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research Ver comentarios Condiciones y Pol\u00edtica de privacidad Privacy Dashboard Historias recomendadas", "symbol": "CTMX", "date": "2025-01-16T15:49:00+00:00", "sentiment": {"score": 0.9330836664885283, "confidence": 0.9493973255157471, "probabilities": {"positive": 0.9493973255157471, "negative": 0.01631365902721882, "neutral": 0.034288980066776276}}, "embedding": [-0.01353865023702383, -0.04998571425676346, -0.04876819625496864, -0.06284934282302856, 0.027183253318071365, -0.029986536130309105, -0.08759652823209763, 0.2930682599544525, 0.1219993382692337, 0.07081909477710724, -0.058682940900325775, 0.05192435160279274, 0.024159036576747894, 0.14050917327404022, -0.00043758563697338104, -0.038907554000616074, 0.03821208328008652, -0.09908783435821533, -0.1738854944705963, 0.08926616609096527, 0.04628072679042816, 0.0348241813480854, 0.015543682500720024, 0.025374360382556915, -0.07313785701990128, 0.035730984061956406, -0.15206627547740936, -0.028968803584575653, -0.08426926285028458, 0.04483605921268463, 0.05825114995241165, 0.14101505279541016, 0.05938924849033356, -0.06221875548362732, -0.07064523547887802, -0.02312469482421875, -0.12776954472064972, 0.08082281053066254, -0.13185957074165344, 0.04622329771518707, -0.11495620012283325, 0.024328377097845078, -0.04393380507826805, -0.03259880840778351, 0.04377086088061333, -0.006894347723573446, -0.06907889246940613, 0.047505319118499756, 0.04341839626431465, 0.1963518261909485, -0.09786377847194672, -0.07155251502990723, -0.00902784988284111, 0.15307360887527466, -0.11738771200180054, -0.006104802712798119, -0.24008837342262268, -0.11689680814743042, -0.020106030628085136, -0.04538080096244812, -0.08850500732660294, 0.018543774262070656, 0.07236459106206894, 0.04320428892970085, -0.07008416950702667, 0.028687290847301483, 0.015369326807558537, -0.07310459017753601, -0.0583551824092865, 0.06146010011434555, 0.10008664429187775, -0.13029661774635315, -0.03778599575161934, 0.16601574420928955, -0.14134256541728973, 0.1646062284708023, 0.1581198126077652, -0.01080811396241188, 0.1999303102493286, -0.13172945380210876, 0.12851250171661377, 0.041389644145965576, 0.08143246173858643, -0.003481651656329632, 0.04471708461642265, -0.016953546553850174, 0.06000657379627228, 0.09368057548999786, 0.06257971376180649, 0.0690203532576561, 0.14876480400562286, 0.03681246191263199, 0.04288426414132118, 0.07779586315155029, 0.10276231169700623, -0.05058508366346359, -0.04753347486257553, 0.10752099752426147, -0.04384825751185417, -0.03010210208594799, 0.051102060824632645, -0.15722036361694336, 0.0010659340769052505, -0.08794784545898438, -0.049622543156147, -0.08035121858119965, 0.13353678584098816, -0.0943271741271019, 0.11228851974010468, 0.04606398567557335, -0.12174375355243683, 0.10553295910358429, 0.05845550447702408, -0.1794169545173645, -0.07387106120586395, 0.31724604964256287, -0.03987665846943855, -0.04170020669698715, 0.17904692888259888, 0.011519466526806355, 0.11621864885091782, -0.13136041164398193, 0.042684156447649, -0.034315235912799835, 0.14938059449195862, -0.0054739005863666534, -0.07816414535045624, 1.0435274040588265e-32, -0.09683353453874588, -0.00963592529296875, 0.08694490045309067, 0.06054043397307396, -0.12107481062412262, -0.04216912388801575, 0.08067396283149719, -0.05836398899555206, -0.10871608555316925, -0.13229340314865112, -0.14790821075439453, 0.07433559000492096, 0.00978851318359375, 0.19797596335411072, -0.07959799468517303, -0.00911732017993927, -0.030588820576667786, 0.010693700984120369, -0.08382170647382736, -0.07286126911640167, 0.14269331097602844, 0.0017675040289759636, -0.015342719852924347, 0.07446641474962234, 0.030131682753562927, -0.06958135962486267, -0.10900288820266724, 0.027267880737781525, 0.0034850649535655975, 0.019543243572115898, -0.02219691313803196, 0.006962125189602375, 0.011936177499592304, -0.10771209001541138, -0.19441086053848267, -0.006818320602178574, -0.16297796368598938, -0.044498611241579056, -0.06210663169622421, 0.08563365042209625, 0.04759654402732849, 0.09373557567596436, -0.18728725612163544, 0.03807786479592323, 0.11732529103755951, -0.1274004578590393, -0.20856115221977234, -0.00384619296528399, -0.062058527022600174, 0.006724159233272076, 0.02406642958521843, -0.06657081097364426, -0.07107414305210114, -0.010236312635242939, -0.03465723991394043, 0.15320196747779846, -0.08992619812488556, -0.020758863538503647, 0.05499120429158211, -0.00875823199748993, 0.03283553943037987, 0.09465083479881287, 0.024838849902153015, 0.10124389827251434, -0.10682171583175659, 0.055115628987550735, 0.10287448763847351, -0.09707646071910858, -0.11780314147472382, 0.035902705043554306, -0.07196004688739777, -0.05828258395195007, 0.11713622510433197, -0.04895763471722603, -0.022907963022589684, -0.10164932161569595, -0.0036351378075778484, 0.062398433685302734, 0.022731928154826164, -0.03300881385803223, 0.02326454594731331, -0.0404776930809021, 0.010262653231620789, 0.21165870130062103, 0.0014222105965018272, -0.07287241518497467, 0.03758885711431503, 0.0687529519200325, -0.1730991005897522, -0.0832786038517952, 0.21750520169734955, 0.026411889120936394, -0.041117068380117416, 0.029820641502738, 0.035260092467069626, -1.0219343809865872e-32, -0.03840859606862068, 0.024369902908802032, -0.02426145412027836, -0.033641502261161804, -0.01354927383363247, 0.2589656114578247, 0.10296537727117538, -0.10162386298179626, 0.1774008870124817, -0.2235887050628662, 0.0005129799246788025, 0.0070957038551568985, -0.021886073052883148, -0.005058372858911753, -0.07585301995277405, 0.007684324402362108, -0.04460778087377548, -0.018017690628767014, -0.10506558418273926, 0.10643146932125092, 0.07939852029085159, 0.017498942092061043, -0.02502164989709854, 0.05669480562210083, 0.005686224438250065, 0.040897540748119354, 0.12981411814689636, 0.08381140232086182, 0.05742039531469345, -0.07723787426948547, -0.03112037479877472, 0.01464739628136158, -0.18705832958221436, 0.060185082256793976, 0.04891692101955414, -0.03686097264289856, 0.04223022609949112, -0.12795928120613098, -0.09256023168563843, -0.168445885181427, -0.04010995477437973, 0.015528050251305103, 0.004263719543814659, 0.006105121225118637, 0.011505289934575558, 0.07526469975709915, 0.15116751194000244, -0.12770457565784454, 0.08062814921140671, -0.11127561330795288, -0.04129040613770485, -0.04991928115487099, 0.015920650213956833, 0.13357147574424744, 0.06047704443335533, -0.05050978064537048, -0.05403769016265869, -0.1299908608198166, -0.10556122660636902, 0.04139353334903717, 0.05996432900428772, 0.1207645833492279, 0.029943741858005524, -0.1511899083852768, 0.014941006898880005, 0.02791908010840416, -0.046028316020965576, -0.03137623891234398, 0.05405930429697037, -0.06827546656131744, -0.09524179995059967, -0.11648397892713547, -0.16959339380264282, -0.06780371814966202, -0.0027905977331101894, 0.1266821175813675, 0.08249769359827042, -0.09082981944084167, -0.09854808449745178, -0.026273274794220924, -0.027470290660858154, -0.020391609519720078, -0.013924597762525082, 0.0037779631093144417, 0.05286087840795517, 0.026098893955349922, 0.030062733218073845, -0.05839383602142334, 0.07416084408760071, 0.11942771077156067, -0.0972723439335823, -0.09995894879102707, -0.016269363462924957, 0.02055954374372959, 0.011887287721037865, -1.0055386212570738e-07, 0.04590490087866783, -0.05296134203672409, 0.07870086282491684, 0.01668389141559601, 0.006334931124001741, 0.0005363877862691879, 0.048170141875743866, 0.020437203347682953, -0.03759884461760521, 0.13689249753952026, 0.09595819562673569, 0.11712807416915894, -0.01979879103600979, -0.06379461288452148, 0.013423999771475792, 0.011351154185831547, -0.06797758489847183, 0.07950890809297562, 0.004286094103008509, 0.017480747774243355, -0.10264447331428528, -0.012052035890519619, 0.03790030628442764, -0.15011657774448395, 0.12862685322761536, 0.01650359481573105, 0.048391565680503845, 0.021441303193569183, -0.014202608726918697, 0.009072515182197094, -0.16337773203849792, -0.022409183904528618, 0.05655107647180557, 0.03264395147562027, -0.06016082316637039, -0.04337364807724953, 0.13391751050949097, 0.08921845257282257, 0.029559649527072906, 0.034715455025434494, 0.09213045239448547, 0.06572268158197403, 0.0022222299594432116, -0.04326675087213516, 0.09920386970043182, 0.0014360323548316956, -0.060065027326345444, -0.09994059801101685, 0.02807450294494629, -0.15364457666873932, -0.009211546741425991, -0.028325634077191353, -0.003329576924443245, 0.020390598103404045, -0.0852784514427185, 0.17954683303833008, -0.14834418892860413, -0.08107917010784149, 0.05032200366258621, -0.021431872621178627, -0.03125392645597458, -0.11626671254634857, -0.006325493101030588, 0.0901954248547554], "changes": {"1wk": 2.4793350626890267}}, {"text": "ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised) Zacks Equity Research Thu, Jan 16, 2025, 5:28 PM 4 min read Acadia Pharmaceuticals ACAD announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for trofinetide to treat Rett syndrome in adults and pediatric patients aged two years and above. An approval in the EU is expected in the first quarter of 2026. If approved in the European Union, trofinetide will become the first and only approved therapy for Rett syndrome in the region. The MAA also marks ACAD\u2019s first regulatory filing for a product in Europe. Trofinetide is already approved in the United States under the trade name Daybue for treating Rett syndrome in adult and pediatric patients aged two years and older. Daybue was launched in the United States in April 2023 and is the first and only drug to be approved by the FDA for the given indication. In the past year, shares of Acadia have plunged 41.6% compared with the industry\u2019s decline of 14.8%. Zacks Investment Research Image Source: Zacks Investment Research ACAD's MAA Based on the LAVENDER Study The MAA for trofinetide in the EU was based on positive data from the phase III LAVENDER study. The LAVENDER study evaluated the safety and efficacy of trofinetide in 187 female patients aged between five to 20 years with Rett syndrome against treatment with a placebo. The study met both its co-primary endpoints, showing statistically significant improvements in treatment with Daybue against placebo, as measured by the change from baseline in the Rett Syndrome Behaviour Questionnaire (RSBQ) total score and the Clinical Global Impression-Improvement (CGI-I) scale score at week 12. The RSBQ is a caregiver assessment that evaluates a range of symptoms of Rett syndrome. The key secondary endpoint of the study, which measured the change from baseline to week 12 in the Communication and Symbolic Behavior Scales Development Profile Infant-Toddler Checklist\u2013Social composite score (CSBS-DP-IT\u2013Social), was also statistically significant versus placebo. A potential approval and launch of trofinetide in the EU are likely to boost ACAD\u2019s growth prospects. ACAD's Other Pipeline Goals for 2025-2026 We note that Acadia\u2019s first drug, Nuplazid (pimavanserin), is approved in the United States for the treatment of hallucinations and delusions associated with Parkinson\u2019s disease psychosis. In a separate press release, the company announced that it expects to generate more than $1 billion in combined net sales for Nuplazid and Daybue in 2025. Acadia is evaluating its pipeline candidate, ACP-101, in the phase III COMPASS PWS study for the treatment of Prader-Willi Syndrome (PWS). Enrollment of the last patient in the study is likely to be completed in the fourth quarter of 2025, while top-line data from the same is expected in the first half of 2026. Story Continues Acadia is developing another pipeline candidate, ACP-204, in the phase II RADIANT study for treating Alzheimer\u2019s disease psychosis. Enrollment of the last patient in the study is likely to be completed in the first quarter of 2026, with top-line data from the same expected in mid-2026. The company also plans to initiate a phase II study on ACP-204 for a second indication \u2013 Lewy Body Dementia \u2013 in the third quarter of 2025. ACAD's Zacks Rank & Stocks to Consider Acadia currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Voyager Therapeutics, Inc. VYGR, CytomX Therapeutics, Inc. CTMX and Castle Biosciences, Inc. CSTL, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today\u2019s Zacks #1 Rank stocks here . In the past 60 days, estimates for Voyager Therapeutics\u2019 loss per share have narrowed from $1.72 to $1.48 for 2025. In the past year, shares of VYGR have plunged 33%. VYGR\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 120.87%. In the past 60 days, estimates for CytomX Therapeutics\u2019 loss per share have narrowed from 46 cents to 35 cents for 2025. In the past year, shares of CTMX have plunged 49.5%. CTMX\u2019s earnings beat estimates in two of the trailing four quarters while missing the same on the remaining two occasions, the average surprise being 115.70%. In the past 60 days, estimates for Castle Biosciences\u2019 loss per share have narrowed from $1.88 to $1.84 for 2025. In the past year, shares of CSTL have surged 31.5%. CSTL\u2019s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%. (We are reissuing this article to correct a mistake. The original article, issued on January 15, 2025, should no longer be relied upon.) Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Voyager Therapeutics, Inc. (VYGR) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CTMX", "date": "2025-01-16T14:28:00+00:00", "sentiment": {"score": 0.5951138958334923, "confidence": 0.6912054419517517, "probabilities": {"positive": 0.6912054419517517, "negative": 0.09609154611825943, "neutral": 0.21270307898521423}}, "embedding": [-0.11146935075521469, -0.034812554717063904, -0.08419844508171082, -0.058715395629405975, -0.07351043820381165, 0.018725086003541946, -0.09440959990024567, 0.30316033959388733, 0.08101391792297363, 0.0258326418697834, -0.010567139834165573, 0.028430981561541557, 0.0041831908747553825, 0.017489800229668617, -0.1046885997056961, 0.011683881282806396, 0.1282598078250885, -0.045909203588962555, -0.005529478192329407, -0.04366018623113632, 0.00587935745716095, 0.03819585219025612, 0.0638955608010292, 0.025573015213012695, -0.14054003357887268, 0.036608751863241196, -0.14478042721748352, -0.08641581237316132, -0.057050470262765884, 0.058018047362565994, 0.0942230373620987, 0.12634052336215973, 0.02178867533802986, -0.11681969463825226, -0.1214514821767807, 0.06424908339977264, -0.14323285222053528, 0.04508325085043907, -0.07435815781354904, -0.0034850146621465683, -0.0310958418995142, -0.16419044137001038, -0.1088482066988945, -0.0714024156332016, 0.055025845766067505, -0.22162362933158875, -0.003965632524341345, 0.11118276417255402, -0.07855091243982315, 0.20178969204425812, -0.08364886045455933, -0.16290977597236633, -0.002266479656100273, 0.15849018096923828, -0.13725659251213074, 0.04153905808925629, -0.17351600527763367, 0.06494492292404175, 0.01623845286667347, 0.09037892520427704, -0.12285482883453369, -0.006128547713160515, -0.0005173911340534687, -0.032018810510635376, 0.1314610242843628, 0.0637979730963707, -0.10920481383800507, -0.07924413681030273, 0.10057789087295532, -0.05456186830997467, 0.0996856540441513, -0.17103156447410583, 0.03878605365753174, 0.18223191797733307, 0.04516655579209328, 0.12079174071550369, 0.07385596632957458, 0.027361739426851273, 0.08020652830600739, -0.1272604912519455, 0.04638461768627167, 0.13737930357456207, -0.02862732857465744, 0.01962803490459919, 0.08513392508029938, -0.0225941501557827, 0.03803825378417969, 0.0795818492770195, -0.027982087805867195, 0.06546603888273239, 0.1934932917356491, 0.051461391150951385, -0.06868867576122284, 0.06742626428604126, 0.019481942057609558, -0.08180761337280273, -0.154852956533432, 0.07508958131074905, -0.12364885210990906, -0.049141548573970795, 0.023358836770057678, 0.04882735386490822, -0.08218338340520859, 0.012282091192901134, -0.15916647017002106, -0.06361179053783417, 0.061619482934474945, -0.07562728226184845, 0.018069442361593246, 0.01504024863243103, -0.2648388147354126, 0.004847189411520958, 0.03956959396600723, -0.06835252046585083, -0.06753633916378021, 0.05333856865763664, -0.002293221652507782, 0.002580457367002964, 0.23131605982780457, -0.08536253124475479, 0.0392940528690815, 0.09222351759672165, 0.047846585512161255, -0.105249784886837, 0.05752578377723694, 0.033382121473550797, -0.05091752111911774, 1.2588762793563402e-32, -0.1546451449394226, 0.06324580311775208, 0.042379338294267654, 0.034420475363731384, -0.04554722085595131, 0.041116468608379364, -0.007699136156588793, -0.008004270493984222, 0.01575625315308571, -0.100257508456707, -0.08681794255971909, 0.020831597968935966, -0.019680552184581757, 0.09959167242050171, 0.002650826470926404, -0.024037403985857964, 0.0003289952874183655, 0.047791484743356705, 0.004525212571024895, 0.03363024815917015, -0.04388050734996796, 0.04200311377644539, 0.009452599100768566, 0.11579740047454834, 3.6636367440223694e-05, 0.01699739322066307, -0.03535015881061554, 0.12733349204063416, -0.09497561305761337, 0.04541577771306038, -0.03592149168252945, 0.03622661530971527, 0.006085751578211784, -0.22972163558006287, -0.17690397799015045, -0.08430792391300201, 0.03264794126152992, -0.07319973409175873, -0.06878117471933365, -0.016032684594392776, -0.05534643679857254, 0.08336667716503143, -0.07383033633232117, 0.07509010285139084, 0.11136995255947113, -0.09588687121868134, -0.11918201297521591, -0.04141087085008621, 0.029338974505662918, -0.03716684877872467, 0.01463736966252327, -0.008950545452535152, -0.013744166120886803, -0.08405125886201859, -0.1286526620388031, 0.13889145851135254, -0.2188437581062317, -0.005380421876907349, 0.09925093501806259, -0.01248140912503004, 0.14811915159225464, 0.01555665209889412, -0.012361893430352211, -0.05522814393043518, -0.1381000578403473, 0.03331834822893143, -0.004477739334106445, -0.05564773082733154, -0.09927184879779816, 0.032155487686395645, 0.006627698428928852, 0.09033934772014618, 0.17130011320114136, -0.008263959549367428, 0.19414106011390686, -0.10436294227838516, 0.09887044876813889, 0.14948856830596924, 7.580313831567764e-05, -0.053524717688560486, -0.05961189046502113, -0.059312328696250916, 0.07588469237089157, 0.08768157660961151, 0.10881046950817108, -0.06684426963329315, 0.011774642392992973, 0.093084916472435, -0.057307783514261246, -0.05769120156764984, 0.0784512385725975, -0.050211790949106216, -0.045342907309532166, 0.17533622682094574, 0.12187042087316513, -1.3448154958506069e-32, -0.033628448843955994, 0.01661846414208412, -0.009038988500833511, -0.060779184103012085, -0.02275226078927517, 0.048420317471027374, 0.009892599657177925, -0.04125495254993439, 0.13908062875270844, -0.10061905533075333, 0.07413588464260101, -0.012366236187517643, -0.019350295886397362, -0.126683309674263, -0.013169955462217331, 0.051373280584812164, -0.04869106784462929, -0.004399094730615616, -0.039071451872587204, 0.04819522425532341, 0.11751192808151245, 0.10626129806041718, -0.03122628852725029, 0.08318835496902466, 0.05685880780220032, -0.04784257337450981, 0.06606604158878326, 0.09663057327270508, 0.0590238943696022, -0.034458041191101074, -0.01621236652135849, 0.05486227571964264, -0.1634959578514099, 0.10657243430614471, -0.09335683286190033, -0.08280794322490692, -0.06202254816889763, -0.1589924693107605, -0.0871291235089302, -0.03970729559659958, 0.1313529759645462, -0.0044469889253377914, -0.03195562958717346, -0.058060336858034134, -0.02238275296986103, 0.052994776517152786, 0.1284967064857483, -0.06651022285223007, 0.0379762277007103, -0.041332095861434937, 0.11336235702037811, 0.09887857735157013, 0.03779623657464981, 0.02405996434390545, 0.04375985264778137, -0.003404112532734871, 0.036310531198978424, -0.07194310426712036, -0.1292407065629959, 0.06954450905323029, 0.15707017481327057, 0.0781513899564743, -0.05631405487656593, -0.0662783831357956, 0.09703897684812546, -0.004387055989354849, -0.053016774356365204, 0.06200813874602318, 0.06594725698232651, 0.0015041669830679893, -0.007234124466776848, -0.07018692046403885, -0.08787625283002853, -0.13386878371238708, -0.02150961384177208, -0.05434740334749222, 0.024897489696741104, -0.07887664437294006, -0.19162414968013763, -0.11386466026306152, -0.1914316713809967, -0.1017102599143982, 0.004146308172494173, -0.014515572227537632, 0.021276067942380905, 0.005252218805253506, -0.037896499037742615, -0.0881170928478241, -0.012178057804703712, 0.16909223794937134, -0.11109497398138046, -0.08331108838319778, -0.19795729219913483, 0.024816930294036865, 0.05522675812244415, -1.0107070380627192e-07, 0.09262265264987946, -0.03132803365588188, 0.00634607532992959, 0.09168639034032822, 0.030676815658807755, 0.00043539784383028746, -0.09549272060394287, 0.09140549600124359, -0.08069262653589249, 0.07719997316598892, -0.03187159448862076, 0.1420232504606247, -0.08714278787374496, 0.03925148397684097, -0.05683522671461105, -0.05032261088490486, 0.012083126232028008, 0.0940125435590744, 0.025335825979709625, 0.01387830637395382, -0.09303952008485794, 0.06137179955840111, 0.04295176640152931, -0.09428329765796661, -0.02876424975693226, -0.04045213758945465, 0.12981060147285461, 0.09159475564956665, -0.1194971352815628, -0.14316847920417786, 0.04788146913051605, -0.01288169901818037, 0.12177003920078278, -0.0356903076171875, 0.008763229474425316, -0.10633432865142822, 0.06184389442205429, 0.1405092179775238, -0.021429937332868576, 0.11590705811977386, 0.05924030765891075, 0.025984952226281166, 0.037560783326625824, 0.03049732744693756, 0.022604942321777344, -0.04433206468820572, -0.019843120127916336, -0.016876159235835075, 0.07995171844959259, -0.006089965812861919, 0.051083870232105255, 0.024314941838383675, 0.04369065910577774, -0.1371581107378006, 0.051847342401742935, 0.11686799675226212, -0.043863438069820404, -0.11776994168758392, 0.02704808861017227, -0.04023125767707825, 0.12705732882022858, -0.09354476630687714, 0.12152008712291718, 0.020911965519189835], "changes": {"1wk": -1.062574180337617}}]